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DEFINITION AND EPIDEMIOLOGY OF OSTEOSARCOMA
Osteosarcoma is a high-grade, intra-osseous malignancy in which the neoplastic cells produce 
bone (Fig. 1.1) [89]. It is the most common primary bone sarcoma. The World Health Organisation 
(WHO) has defined several major histological subtypes of osteosarcoma (Table 1.1) [217]. High-grade 
osteosarcoma occurs predominantly in children and young adults (Fig 1.2, incidence rate up to 8.4 
per million in children aged 15 to 19 years), with a second peak of incidence in the elderly (incidence 
rate of 4.2 per million in the over 60 years age group) [177;248]. Incidence rates in adults aged 25 to 
59 years are lowest at 1.7 per million. Males are affected more often than females at a ratio of 1.3 to 1.
PATHOGENESIS
Several lines of evidence suggest that osteosarcoma originates from mesenchymal stromal 
cells (MSCs) or early osteoblast precursor cells [181]. High-grade osteosarcoma commonly 
develops at an age and anatomical site of rapid proliferation and differentiation of MSCs, i.e. 
intramedullary near the growth plate of the long bones during or after the pubertal growth 
spurt. Long term in vitro expansion of murine MSCs results in oncogenic transformation of 
the cultured cells which form osteosarcoma-like tumors in vivo [113;116;179;183;259]. A patient 
transplanted with bone marrow (containing hematopoietic stem cells and MSCs) from a sibling 
was diagnosed with an osteosarcoma originating from donor cells 17 years later [19]. These data 
support the hypothesized mesenchymal stromal cell origin of osteosarcoma.
Most osteosarcomas arise sporadically, but some genetic or environmental factors increase 
the risk for developing osteosarcoma. Germ line mutations in the tumor suppressor genes 
TP53 and RB1 are associated with the Li-Fraumeni and hereditary retinoblastoma syndromes, 
respectively, both of which are associated with an increased risk to develop osteosarcoma 
and other types of cancer [231]. Mutations in the helicase genes RECQL2, RECQL3 and RECQL4 
respectively cause Werner, Bloom and Rothmund-Thompson syndrome, all of which are 
associated with an increased risk of developing osteosarcoma [88;117;276]. In several other 
Fig. 1.1 Histology of conventional osteoblastic osteosarcoma. Hematoxylin and eosin stained section of diagnostic 

















cancer syndromes an association with osteosarcoma has been reported, but is less well 
established. For example, according to Chowdry et al., neurofibromatosis type 1 patients have 
a higher than expected incidence of bone sarcomas including osteosarcoma [43].
In a small percentage of osteosarcoma cases pre-malignant conditions can be identified, as 
has been reviewed in [105]. Well known precursor lesions are Paget’s disease, fibrous dysplasia, 
dedifferentiated chondrosarcoma and giant cell tumor of bone [96;105;206]. Patients presenting 
with an osteosarcoma in the context of these conditions are often older than patients in whom 
no precursor lesion is identified.
Radiation exposure, for example in the treatment of other cancers, is the best known 
environmental risk factor in osteosarcoma, accounting for 0.5-5% of all new osteosarcoma 
cases [124;280].
Osteosarcoma is characterized by gross chromosomal instability with very complex polyploid 
karyotypes and marked cell-to-cell heterogeneity [231]. This is in contrast to many other 
sarcomas which can be defined by specific translocations, resulting in specific fusion transcripts, 
such as the EWS-FLI1 transcript in Ewing sarcoma [230]. The highly complex chromosomal 
rearrangements as are present in osteosarcoma can occur as a result of a single catastrophic 
event, termed chromothripsis [72]. However, this probably has to occur in a susceptible 
background, either as a genetic predisposition or acquired as a de novo event. If chromothripsis 
occurs in the development of osteosarcoma and which somatic genetic or epigenetic 
aberration would confer susceptibility in osteosarcoma patients is as yet unknown. No specific 
chromosomal aberrations can be identified in osteosarcoma, but gain of chromosome 1 (present 
in 22% of examined karyotypes) and loss of chromosomes 9, 10, 13, and 17 (in 29%, 37%, 36% and 
30% of specimens, respectively) occur in a significant proportion of osteosarcomas [30]. On 
Table 1.1 Osteosarcoma classification according to the World Health Organisation [217]
Conventional osteosarcoma
- Osteoblastic (including sclerosing)
- Chondroblastic
- Fibroblastic







Low grade central osteosarcoma
Parosteal osteosarcoma (low grade)
Periosteal osteosarcoma (intermediate grade)
















a molecular genetic level, the TP53 and RB1 tumor suppressor pathways are often inactivated, 
resulting in loss of cell cycle control and unchecked cell proliferation [95;183;281].
DIAGNOSIS, TREATMENT AND PROGNOSIS
Most osteosarcomas are localized near the metaphyseal ends of the long bones, particularly in 
the distal femur, proximal tibia and proximal humerus. Patients often present with a history of 
pain and swelling of a few months duration. Symptoms sometimes seem to be precipitated by 
minor trauma. Rarely, patients present with a pathological fracture or functional impairment. 
Systemic symptoms are almost always absent. Radiographic examination usually reveals an 
osteolytic or osteosclerotic lesion with cortical involvement, a periosteal reaction and marked 
soft-tissue involvement (Fig. 1.3) [175]. Diagnostic biopsy of the lesion is required for a definitive 
diagnosis of osteosarcoma and for subtype classification (Fig. 1.1, Table 1.1). Staging studies 
include magnetic resonance imaging of the primary tumor to evaluate soft tissue expansion, 
computed tomography of the chest to evaluate the presence of pulmonary metastases and 
radionuclide bone scanning with technetium to evaluate the presence of bone metastases.
Prognosis for patients with osteosarcoma is mainly determined by the presence or absence 
of metastatic disease. About fifteen percent of patients have detectable metastatic disease at 
diagnosis and about 40 to 50 percent of initially non-metastatic patients subsequently develop 
detectable metastatic disease [172]. Overall survival for patients with metastatic disease is 
very poor at about twenty percent. Another major prognostic factor in osteosarcoma is the 
histological response to neo-adjuvant chemotherapy in the primary tumor, with less than 
ninety percent necrotic tumor area defined as prognostically unfavorable.
Before the introduction of chemotherapy in the management of osteosarcoma in the 
1970s, long term survival rates were about 10% following complete resection of the tumor, 
Fig. 1.2 Most osteosarcomas occur in children and young adults. Age distribution of 274 high-grade osteosarcoma 
patients diagnosed from 1990 to 2009 and treated at the Leiden University Medical Center. A second peak of 
incidence is often reported in the above sixty year age group, but is not apparent in our tertiary referral clinic, 

















implicating that macroscopic or microscopic metastases are present in almost all patients at 
diagnosis. Since the introduction of chemotherapeutic treatment, overall long term survival 
of osteosarcoma has improved to about sixty percent. However, the overall survival rate has 
not improved substantially in the last twenty years, despite clinical trials investigating higher 
dosages and higher dose intensity chemotherapy regimens (Fig. 1.4). Currently, treatment 
consists of several rounds of neo-adjuvant and adjuvant chemotherapy in addition to radical 
surgical treatment of the primary tumor and metastases whenever feasible. Chemotherapeutic 
regimens have typically consisted of doxorubicin and cisplatin with or without high-dose 
methotrexate. Addition of etoposide and high-dose ifosfamide have been used in salvage 
regimens for non-resectable metastatic disease. A recent meta-analysis suggests that 
treatment with four or five drugs may not confer a survival advantage to treatment with a three 
drug regimen [8].  The addition of etoposide and ifosfamide for patients with poor histological 
response to the standard (neo-)adjuvant three drug regimen of methotrexate, adriamycin 
and doxorubicin is currently being evaluated in European and American Osteosarcoma Study 
Group (EURAMOS)-1 trial, for which results are due in 2015-2016 [160].
Fig. 1.3 Conventional radiograph demonstrating an osteosarcoma 
of the right femur in a 13 year old boy. Note the irregular structure of 
the bony matrix in metaphysis and diaphysis, the periostal reaction 
















INNATE IMMUNITY IN OSTEOSARCOMA PATIENTS
The innate immune system is the first-line defense system against pathogens and consists 
of physical barriers, cellular components and humoral components. Cellular components of 
the innate immune system such as granulocytes and macrophages are able to recognize and 
phagocytose pathogens through interaction of intracellular and surface membrane receptors 
with pathogen associated molecular patterns (PAMPs). Natural killer (NK) cells recognize and lyse 
virus infected cells when the balance of signals transduced via inhibitory and activating NK cell 
receptors is shifted towards activation [213]. There is increasing evidence that cells of the innate 
immune system such as macrophages and NK cells are able to not only detect and kill pathogens, 
but also tumor cells. In this thesis, we have studied the interaction between cells of the innate 
immune system -in particular macrophages and NK cells- and osteosarcoma cells, with the aim to 
provide preclinical data to guide future trials employing immunotherapeutic strategies.
Tumor-associated macrophages and cancer immunology
Infiltration of tumors with macrophages is often associated with worse prognosis. Several 
mechanisms have been proposed to explain the pro-tumorigenic effect of tumor-associated 
macrophages (TAMs). First, TAMs can express matrix-degrading proteins and thus facilitate 
tumor cell evasion and metastasis. Matrix metalloproteinase (MMP) expression by tumor 
stromal cells is associated with worse prognosis in many tumor types and MMP-9 expression 
by hematopoietic cells was essential for tumor progression in a murine squamous cell 
carcinoma model [50;63]. Second, TAMs can support angiogenesis through expression of 
specific cytokines and growth factors, for example vascular endothelial growth factor (VEGF), 
urokinase plasminogen activator and C-X-C chemokine receptor (CXCR)-2 ligands such as 
C-X-C chemokine ligand (CXCL)-8 [3;5;48;142]. Third, TAMs excrete immunosuppressive 
cytokines  such as interleukin (IL)-10 and transforming growth factor- β (TGF-β), consequently 
hampering effective anti-tumor immunity [70;238]. These tumor promoting TAMs have many 
Fig. 1.4 Overall survival of osteosarcoma patients has not improved significantly since the 1990s (data of 274 high-

















characteristics in common with ‘alternatively’ IL-4 and IL-13 activated M2 type macrophages. 
M2 type macrophages express the scavenger receptor CD163 and have important tissue 
regenerative roles, for example in wound healing and angiogenesis. It is these homeostatic 
features that also promote growth and dissemination of tumor cells. Intratumoral infiltration 
with M2, or ‘alternatively activated’ macrophages is associated with increased angiogenesis, 
metastasis and decreased survival in many tumors, including sarcomas [78;138;266].
In contrast, ‘classical activation’ of macrophages by interferon-γ or microbial products results 
in expression of high levels of pro-inflammatory cytokines, such as IL-12, IL-1 and IL-6 [188]. These 
so-called M1 type macrophages have potent anti-tumor efficacy. They are able to kill tumor cells 
directly, through phagocytosis of tumor cells, reactive oxygen species and cytokine-induced 
cytotoxicity [109]. Additionally, they can recruit and activate NK and T cells and can initiate an 
adaptive immune cell response. In rare instances, high numbers of TAMs are associated with 
better survival of cancer patients [73;122]. It is presumed that the infiltrating macrophages in these 
tumors are polarized towards an M1 phenotype, but this has not been unequivocally proven.
M1 and M2 type activation of macrophages represent extremes of a spectrum (Fig 1.5). 
Macrophages demonstrate considerable phenotypic plasticity. Under the influence of 
environmental factors, polarization towards one or the other activation status can occur. To 
exploit this plasticity in an immunotherapeutic context, tumor resident M2 type macrophages 
may be classically activated towards an M1 phenotype by microbial cell products, or PAMPs. 
The successful utilization of immunostimulation in the treatment of sarcomas was first 
demonstrated by William B. Coley in 1891 [49;246]. Coley injected a mixture of streptococcal 
toxins into unresectable tumors and observed tumor regression in several sarcoma patients. 
More recently, post-operative infection has been shown to be associated with a better 
survival in osteosarcoma patients, possibly through activation of the innate immune system 
[114;136;242]. Treatment of osteosarcoma patients with the microbial cell wall product and 
macrophage activating agent muramyl tripeptide (MTP) in addition to standard chemotherapy 
improved overall survival in a recent clinical trial, although the exact mechanism remains 
unclear [170]. Another mechanism for classical activation of macrophages is through induction 
of immunogenic cell death. Often, chemotherapy induced cancer cell death is immunologically 
‘silent’. However, as a result of certain cytotoxic treatments, such as alkylating agents, 
oxaliplatin and ionizing radiation, immunogenic cell death can occur . The expression and cell 
surface translocation of damage-associated molecular patterns (DAMPs) such as calreticulin 
and high mobility group protein B1 trigger the activation of antigen presenting cells, similar to 
the response to PAMPs during infection [10;131;193]. 
NK cells
NK cells are innate immune cells that lack a clonally rearranged antigen-specific receptor. They 
have important regulatory functions through the expression of cytokines and chemokines and 
are potent effector  cells. Cytolytic activity depends on the balance of between activating signals 
and inhibitory signals. High expression of ligands for the activating NK cell receptors Natural 
















cytotoxicity receptors (NCRs) NKp30, NKp44 and NKp46 in conjunction with loss of expression 
of the ligands for the inhibitory NK cell receptors Killer Immunoglobulin-like Receptors (KIRs) 
and the C-type lectin heterodimer CD94/NKG2A on tumor cells can render them susceptible to 
NK cell mediated cytotoxicity (Fig. 1.6) [20;26;38;64;118;135;178;186;213;272].
Although NK cells have the natural ability to lyse tumor cells without the need for prior 
sensitization, NK cell mediated anti-tumor activity can be enhanced through the administration 
of NK cell activating cytokines such as IL-2 and IL-15, or the adoptive transfer of ex vivo activated 
NK cells [268;275]. There are several lines of evidence to suggest that treatment with NK 
cells or NK cell activating agents may be an effective adjunct to treatment of osteosarcoma 
patients. Previous pre-clinical studies have shown that osteosarcoma cell lines are sensitive 
to NK cell mediated cytolysis [104;132;143;156-159;165;191]. A murine model of post-operative 
osteomyelitis in osteosarcoma, in which anti-tumor activity was dependent on NK cells and 
monocytes, suggests that NK cell-mediated cytotoxicity also occurs in vivo [242]. A small 
cohort of osteosarcoma patients was treated with IL-2, which resulted in NK cell activation and 
a better outcome [151]. Interferon-α is an anti-proliferative and immunomodulatory cytokine, 
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Fig. 1.5 M1 and M2 type macrophage activation represent extremes of a spectrum. Classically activated M1 
type macrophages exhibit anti-tumor characteristics such as high expression of pro-inflammatory cytokines. 
Alternatively activated M2 type macrophages support tumor growth through tissue homeostatic features such as 

















Fig. 1.6 NK cells engage in target cell lysis when the balance between inhibitory and activating signals is shifted 
towards activation. Adapted from [213].
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administration of which results in activation of immune cell subsets such as monocytes and NK 
cells, in addition to direct anti-proliferative effects on tumor cells [31;62;154]. In Scandinavia, the 
addition of interferon to the treatment regimen of osteosarcoma patients resulted in a better 
















α-2b is currently under study in the EURAMOS-1 trial. Preliminary data suggests no benefit, but 
follow-up of patients is ongoing  [25;160;278].
AIMS AND OUTLINE OF THIS THESIS
A better understanding of the pathogenesis of high-grade osteosarcoma has the potential to 
identify novel targets for (immuno-)therapeutic interventions. MSCs are the proposed cell 
of origin of osteosarcoma. In chapter 2, the results of long term in vitro culture and genetic 
analyses of MSCs from osteosarcoma patients and healthy donors is described, to determine 
if MSCs from osteosarcoma patients are predisposed to malignant transformation.  The main 
cause of death for osteosarcoma patients is pulmonary metastatic disease. In chapter 3, 
prognostic factors in pulmonary metastasized osteosarcoma patients are identified. This will 
aid in determining which patients are most likely to benefit from novel treatment modalities. 
In the next chapters, the constitutive in vivo interactions between the innate immune system 
and high-grade osteosarcoma are studied. Possible avenues for therapeutic exploitation of 
anti-osteosarcoma immunopotency are studied through in vitro manipulation of immune 
and target cells. In chapter 4 the prognostic significance of intratumoral infiltration with 
macrophages is presented. In chapter 5 cytotoxic activity of NK cells towards (chemotherapy 
resistant) osteosarcoma cells is studied. The recently closed EURAMOS-1 trial randomizes 
for treatment with interferon-α in patients with good histological response to neo-adjuvant 
chemotherapy [160]. In chapter 6, the molecular and functional effects of interferon treatment 
on the activation and anti-tumor activity of peripheral blood lymphocytes and monocytes of 
osteosarcoma patients, both in vivo and ex vivo is shown. In chapter 7, the findings of this thesis 
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ABSTRACT
In vitro expanded mesenchymal stromal cells (MSCs) are increasingly used as experimental 
cellular therapy. However, there have been concerns regarding the safety of their use, 
particularly with regard to possible oncogenic transformation. MSCs are the hypothesized 
precursor cells of high-grade osteosarcoma, a tumor with often complex karyotypes occurring 
mainly in adolescents and young adults. To determine if MSCs from osteosarcoma patients 
could be predisposed to malignant transformation we cultured MSCs of nine osteosarcoma 
patients and five healthy donors for an average of 649 days (range 601-679 days). Upon 
increasing passage, increasing frequencies of binucleate cells were detected, but no malignant 
transformation occurred in MSCs from either patients or donors. Also, we compared MSCs 
derived from osteosarcoma patients at diagnosis and from healthy donors using genome wide 
gene expression profiling. Hematopoietic cell specific Lyn substrate 1 (HCLS-1) was differentially 
expressed (fold change 0.25, P-value 0.0005) between MSCs  of osteosarcoma patients (n=14) 
and healthy donors (n=9). In conclusion, this study shows that despite downregulation of 
HCLS1 in MSCs of osteosarcoma patients and occurrence of binucleate cells in patient and 
donor derived MSCs, spontaneous transformation does not occur during long-term culture. 
In contrast to what has been reported for certain animal species, administration of ex vivo 
expanded human MSCs for therapeutic purposes is unlikely to result in sarcomas.
INTRODUCTION
Mesenchymal stromal cells (MSCs) are increasingly used as experimental cellular therapy in a wide 
range of conditions, such as graft-versus-host disease in the context of allogeneic bone marrow 
transplantation, auto-immune diseases  and for regenerative purposes in for example myocardial 
injury or cartilage defects [15;46;137;198;264;274]. However, since MSCs have to be expanded in 
vitro to achieve sufficient numbers, there have been concerns regarding the safety of their use, 
particularly with regard to possible oncogenic transformation [219]. Cultured murine MSCs readily 
transform and form sarcoma-like tumors in vivo [113;116;179;183;259]. Similarly, MSCs derived from 
rhesus macaques become polyploid and subsequently aneuploid during long-term culture [107]. In 
contrast, human MSCs appear resistant to spontaneous in vitro transformation [22]. Studies reporting 
that human MSCs undergo malignant transformation in vitro have been retracted because of cross-
contamination issues [56;218;221-223;260]. Despite the apparent difference between human and 
murine MSCs in their propensity to spontaneously transform in vitro, concerns remain. MSCs are 
hypothesized to be the precursor cells of high-grade osteosarcoma (OS) and a patient transplanted 
with bone marrow (containing hematopoietic stem cells and MSCs) from a sibling was diagnosed 
with OS originating from donor stem cells 17 years later [19]. This case demonstrates that donor-
derived (pre-) cancerous MSCs can survive in a host and cause disease many years later. Another 
cause for concern is the observation that cultured MSCs can acquire chromosomal aberrations, 
although these do not seem to confer a selective growth advantage in vitro [18;254].
High-grade osteosarcoma is a malignant primary bone tumor which often occurs at a relatively 
young age [2]. OS tumor cells are characterized by aneuploid karyotypes and gross chromosomal 
instability [251]. Such highly complex chromosomal rearrangements can occur as a result of a 
single catastrophic event, termed chromothripsis [102;247]. However, this probably has to occur 
in a susceptible background, either as a genetic predisposition or acquired as a de novo event. In 
a murine model failed cytokinesis can lead to tetraploidy and subsequent tumorigenesis only in a 
p53 deficient host [77]. We previously showed loss of CDKN2A/p16 protein expression in tetraploid 
tumorigenic murine MSCs [183]. We hypothesized that normal MSCs from OS patients could be 
predisposed to malignant transformation, which might be identified by comparison of genome 
wide expression profiles of early passage MSCs from OS patients and healthy donors. Also, the 
presence of a pro-oncogenic predisposition could result in higher rates of spontaneous in vitro 
transformation during long-term culture. On the other hand, failure of these patient-derived cells 
to transform in vitro would be in line with previous reports in healthy individuals that spontaneous 
transformation of human MSCs in vitro is an extremely unlikely event. This would support the 
notion that therapeutic use of cultured (bone marrow-derived) MSCs is safe.
MATERIALS AND METHODS
Patients
Characteristics of OS patients and healthy stem cell donors can be found in Table 1. Bone 
marrow cells of OS patients were harvested under general anesthesia prior to start of the 





























location of the primary tumor (metaphyseal ends of the long bones) in all cases. Healthy donors 
were either identical sibling donors for patients with malignant or benign disease requiring 
hematopoietic stem cell transplantation; or haploidentical donors for either hematopoietical 
stem cell transplantation or the therapeutic infusion of MSCs for steroid-resistant graft-versus-
host disease. Written informed consent was obtained from all patients and donors prior to 
bone marrow harvesting. The study was approved by the Institutional Review Board on Medical 
Ethics (LUMC Medical Ethics Committee (CME), P06.152).
Mesenchymal stromal cell cultures
Bone marrow derived mononuclear cells were obtained from 5 to 15 ml of heparinized bone 
marrow aspirate by density gradient centrifugation on Ficoll. Cells were plated on non-coated 75 
cm2 polystyrene flasks at a cell density of 160000/cm2 in complete culture medium (LG-DMEM; 
Invitrogen, Paisley, United Kingdom) supplemented with penicillin/streptomycin (Invitrogen) and 
10% fetal bovine serum (FBS; HyClone, Verviers, Belgium). We used a characterized and defined 
FBS batch preselected for its potential to support MSC expansion and continued to use this 
specific batch throughout the culture period. MSCs were plastic adherent and had spindle shaped 
morphology.  Chondrogenic, adipogenic and osteoblastic differentiation were performed as 
described earlier [21]. Medium was refreshed twice a week and cells were replated when reaching 
80-90% confluence at a density of 4000/cm2. The first nine OS patient and first five healthy donor 
MSC samples that were obtained were cultured long-term, the subsequent samples were used 
for confirmatory mRNA expression analysis (Table 1). Morphology of the cells was recorded and 
population doublings per passage (PD) were calculated using the log ratio of the harvesting cell 
count (N) to the starting (baseline) count (X0), divided by the log of 2 (PD = [log (N / X0)]/ log 2).
Flow cytometry
Expression of the cell surface markers CD73, CD90 and CD105 and absence of hematopoietic 
markers on MSCs was determined using flow cytometry, according to the statement by the 
International Society for Cellular Therapy [58]. Cells were detached using Trypsin/EDTA and 
washed in PBS/0,05% bovine serum albumin. Antibodies used were conjugated anti-CD86-
fluorescein isothiocyanate (FITC) (cat. no. 555657), anti-HLA-DR-FITC (cat. no. 347400), anti-
CD31-phycoerythrin (PE) (cat no 555446), anti-CD34-PE (cat no 348057), anti-CD73-PE (cat no 
550257), anti-CD90-PE (cat no 555596), anti-CD3-peridinin chlorophyll protein(PerCP)-Cy5.5 (cat 
no 332771), anti-CD45-PerCPCy5.5 (cat no 332784), all from BD (San Diego, CA) and anti-CD105-
PE (cat no SN6), from Ancell (Bayport, MN). Flow cytometry was performed on a FACScalibur, 
and analyzed using Cellquest software (both Becton Dickinson). Mean fluorescence intensity 
(MFI) ratio was calculated by determining the MFI of the specific staining relative to the MFI of 
the appropriate isotype control staining.
Analysis of binucleate cells
MSCs were grown on coverslips. Coverslips were washed with PBS and fixed in 4% PFA. Coverslips 
were incubated for ten minutes in 1μg/mL acridine orange (Sigma-Aldrich, Zwijndrecht, the 
















conjugate (Invitrogen) in PBS to stain cell membranes. Following washes in PBS, coverslips were 
mounted using Vectashield with DAPI (Vector laboratories, Burlingame, CA) to stain nuclei. Images 
were acquired using a COHU 4910 series monochrome CCD camera (COHU, San Diego, CA) 
attached to a DM fluorescence microscope (Leica, Wetzlar, Germany) and analyzed using ImageJ 
software with the Cell Counter plug-in (National Institute of Mental Health, Bethesda, MD).
RNA isolation 
RNA was isolated from frozen cell pellets of at least 1*10e6 undifferentiated MSCs at passage 2 
to 5 using TRIzol reagent (Invitrogen). Cells were lysed in TRIzol, followed by phase separation 
in chloroform, precipitation using 2-propanolol and washing in 75% ethanol. RNA clean-up was 







Location of the 
primary tumor
Included in experiment:
Microarray qPCR Long-term culture
001OS OS(352) M 12 Osteoblastic Distal femur y y y
002OS OS(340) F 13 Osteoblastic Distal femur y y y
003OS OS(376) F 13 Telangiectatic Distal femur y y y
004OS OS(377) F 14 Sclerosing Proximal tibia y y y
005OS OS(348) F 15 Telangiectatic Distal tibia n n y
006OS OS(349) M 8 Osteoblastic Distal femur y y y
007OS OS(350) F 15 Osteoblastic Distal femur n n y
008OS OS(378) F 9 Osteoblastic Proximal humerus y y y
009OS OS(382) M 15 Chondroblastic Proximal humerus y y y
010OS OS(388) M 14 Osteoblastic Proximal humerus n y n
011OS OS(391) F 14 Osteoblastic Proximal tibia n y n
012OS OS(394) F 5 Osteoblastic Distal femur n y n
013OS OS(393) F 14 Osteoblastic Distal femur n y n
014OS OS(395) M 10 Sclerosing Distal femur n y n
015OS OS(396) M 13 Osteoblastic Distal femur n y n
016OS OS(402) F 15 Sclerosing Proximal tibia n y n
HB HD(HB) M 15 y y y
HD3 HD(HD3) F 27 y y y
HD5 HD(HD5) M 50 y y y
MH HD(MH) M 15 y y y
TD1 HD(TD1) F 11 y y y
TD2 HD(TD2) F 43 n y n
TD3 HD(TD3) F 43 n y n
TD4 HD(TD4) F 25 n y n





























performed using the QIAGEN Rneasy mini kit (Venlo, the Netherlands) with on-column DNAse 
treatment. RNA quality and concentration were measured using an Agilent 2100 Bioanalyzer (Santa 
Clara, CA) and Nanodrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA), respectively.
cDNA synthesis, cRNA amplification, and Illumina Human v2.0 
Expression BeadChip hybridization
Gene expression profiling was performed using Human-6 v2 Expression BeadChips (San 
Diego, CA) containing >48,000 transcript probes. Synthesis of cDNA, cRNA amplification, and 
hybridization of cRNA onto the Illumina Human v2.0 Expression BeadChips were performed as 
described previously [33;94].
qPCR
cDNA synthesis for qPCR was performed as described earlier [33]. qPCR was performed using the 
iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, CA) according to the manufacter’s instructions, 
reverse transcriptase negative (RT-) and H
2
O controls were taken along for each sample. For 
normalization, three genes with stable expression in the microarray experiments were chosen 
(CPSF6, GPR108 and CAPNS1). Data were normalized by geometric mean expression levels of 
the three reference genes using geNorm (http://medgen.ugent.be/jvdesomp/genorm/). 
Primer sequences can be found in Table S1. A standard curve was taken along for each primer 
set and used for quantification, PCR efficiencies ranged from 93 to 104%.
Karyotyping
Six early passage samples (three derived from OS patients, three derived from healthy donors) 
were subjected to a multicolor FISH based karyotyping test (COBRA-FISH) as described earlier 
[253]. From each sample at least twenty metaphase cells were recorded and analyzed.
Statistical analysis
Microarray data were normalized using the Cubic Spline normalization method with the Illumina 
BeadStudio Gene Expression Module. Microarray data are available at GEO using the accession 
no. GSE42572. Statistical analysis of microarray was performed using Significance Analysis for 
Microarrays, using a false discovery rate of 20% (SAM, http://www-stat.stanford.edu/~tibs/SAM/) 
[263]. Univariate statistical analyses were performed using GraphPad Prism software (version 5.01, 
La Jolla, CA). Two-sided P-values lower than 0.05 were determined to be significant.
RESULTS
MSCs of OS patients and healthy donors do not differ in expression of 
cell surface markers or differentiation capacity
We tested the MSC cultures from OS patients and healthy donors for phenotypic markers 
and functionality. Samples from 16/16 patients and 9/9 controls were able to differentiate into 
chondrogenic (Suppl. Fig. 2.1a), adipogenic (Suppl. Fig 2.1b and c) and osteoblastic lineages 
















expression of hematopoietic markers (Suppl. Fig. 2.1f). Level of expression of CD73, CD90 
and CD105 as determined by MFI-ratios (specific staining/isotype control) did not differ 
between MSC cultures derived from OS patients and healthy donors (data not shown). Early 
passage samples from three OS patient derived MSCs and three healthy donor derived MSCs 
were karyotyped; no structural or numerical aberrations were observed in the analyzed 
samples (Suppl. Fig. 2.2): MSC001: 46,XY (26 metaphases), MSC003: 46,XX (27 metaphases), 
MSC008:46,XX (22 metaphases), MSC-HB: 46,XY (21 metaphases), MSC-MH: 46,XY (20 
metaphases), MSC-TD: 46,XX (21 metaphases).
Long-term in vitro  culture of MSCs results in increased binucleation 
but not in malignant transformation
MSCs of nine OS patients and five healthy donors were long term cultured (average number of 
days in culture 649, range 601-679 days). From each individual sample, duplicate cultures were 
established. There were no significant differences between growth rate, cumulative population 
doublings (median cumulative population doublings OS patients 34 vs. healthy donors 39; P-value 
Mann-Whitney U test 0.70) ), passage number at termination of culture (mean passage number OS 
patients 21 vs. healthy donors 23; P-value Mann-Whitney U test 0.74) or time to growth arrest (median 
days to growth arrest OS patients 441 days vs. healthy donors 222 days; P-value Mann Whitney U test 
0.15) between MSCs of OS patients and healthy donors. The cumulative population doublings are 
shown in Fig. 2.1 (averages of the duplicate cultures are shown per sample). All cultures exhibited 
rapid exponential growth in the first few passages. Later, proliferation slowed down and eventually 
stopped. At termination of the cultures, viable cells were present in all samples. Cultures were 
terminated at the end of the growth curves. At this point, none of the cultures had demonstrated an 
increase in proliferation indicative for spontaneous in vitro malignant transformation.
Morphology of the cells was inspected with every passage. Low passage cells were spindle-
shaped, higher passage cells were larger. Upon increasing passage number, increasing frequencies 
of binucleate cells were noted using phase contrast microscopy. To quantify binucleation, cells 
were grown on coverslips and cytoplasm, cell membranes and nuclei were stained. Mono- and 
binucleate cells were counted (Fig. 2.2a-d). There was no difference in percentage of binucleate 
cells between MSCs derived from OS patients and healthy donors (Fig. 2.2e).
HCLS1  mRNA expression is downregulated in OS patient derived MSCs
Using microarray gene expression analysis, five genes were found to be differentially expressed 
between early passage healthy donor derived MSCs (n=5) and OS patient derived MSCs (n=7), 
with a false discovery rate of 20%. Expression of HCLS1, ADM, EEF1A1, LOC644739 (or WASF4) 
and LOC441155 was lower in patient derived MSCs as compared to healthy donor derived 
MSCs. To perform simultaneous technical and biological validation of the microarray results, 
the original low passage MSC samples were recultured and the original series expanded to 
now include four additional healthy donor derived MSCs (total of n=9) and seven additional 
OS patient derived MSCs (total of n=14). Four of the differentially expressed genes were 





























(ADM), eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) and LOC644739 (or WAS 
protein family, member 4; WASF4). LOC441155 is a pseudogene for which we did not succeed 
in designing a sufficiently specific and efficient primer pair. In this second, newly cultured and 
expanded series, expression of HCLS1 was significantly lower in OS patient derived MSCs as 

























Fig. 2.2 Increased binucleation was noted upon increasing passage number. To facilitate cell staining and counting of 
nuclei, cells were grown on glass coverslips and stained using wheat-germ agglutinin (a, cell membranes), acridine 
orange (b, cytoplasm) and DAPI (c, nuclei), shown in 100x magnification. d, overlay with cell membrane in red, 
cytoplasm in green and nuclei in blue. A representative example of a high passage binucleate cell is shown. Note also 
the presence of a micronucleus (panel c). e, upon increasing passage number, more binucleate cells were noted, but 
no differences were seen between healthy donor-derived and osteosarcoma (OS) patient-derived MSCs (Kruskal-
Wallis test P-value<0.0001, Dunn’s post-test compared to early passage cells; P-value <0.01 noted as **; <0.001 = ***.
Fig. 2.1 Cumulative population doublings of cultured MSCs from nine osteosarcoma (OS) patients and five healthy 
















other genes were not differentially expressed in this series, perhaps because this was a newly 
expanded batch of cells. We tried to determine if the observed difference in HCLS1 expression 
was also true at the protein level. Although HCLS1 protein could be clearly detected in the 
positive control cell line Jurkat, we were unable to reproducibly detect HCLS1 in MSCs (data 
not shown). For five OS patients we had mRNA available from both bone-marrow derived MSCs 
and the primary tumor. In these samples, expression of HCLS1 was higher in tumor tissue as 
compared to MSCs, but there was no correlation between level of expression of HCLS1 in low 
passage MSCs and in the corresponding tumor tissue (data not shown).
Fig. 2.3 Expression of HCLS1 as determined by qPCR in bone-marrow derived MSCs no later than passage 5 is 
lower in MSCs derived from newly diagnosed osteosarcoma patients (OS; n=14) than in MSCs derived from 
healthy donors (HD; n=9). (***); P-value Mann Whitney-U test =0.0005. Expression levels for EEF1A1, ADM and 






























In recent years, MSCs have gained increasing interest as a therapeutic modality for immune 
modulatory and regenerative purposes [46;137;198;264].  In order to achieve sufficient numbers of 
cells for therapeutic utility, MSCs need to be expanded in vitro prior to infusion. Since long-term 
culture of non-human MSCs can result in oncogenic transformation and the occurrence of sarcomas 
in the receiving hosts, there is ongoing debate regarding the safety of using cultured MSCs in clinical 
studies [209]. In the present study, we compared human MSCs derived from OS patients at diagnosis 
and from healthy donors to answer two questions. First, do human MSCs transform to a malignant 
phenotype when cultured in vitro, as has been shown for murine MSCs? Second, are MSCs derived 
from OS patients more likely to transform than healthy donor derived MSCs? 
MSCs from patients and controls exhibited similar growth patterns during long-term in vitro 
culture, and we never observed malignant transformation or increased growth potential, 
even after almost two years of continuous culture. There were no phenotypical or functional 
differences between OS patient derived and healthy donor derived MSCs and early passage 
karyotypes were normal in both groups. Differentiation capacity and expression of specific cell 
surface markers was similar. 
During prolonged culture, progressive shortening of telomeres occurs [123]. This can cause 
anaphase chromatin bridges, resulting in failed cytokinesis and consequently in binucleate 
cells [201]. In the context of loss of expression or function of tumor suppressor proteins and 
corresponding cell cycle checkpoints, tetraploidy and ultimately aneuploidy will occur [77]. Upon 
increasing passage, increasing frequencies of binucleate cells were noted; both in patient derived 
MSCs and healthy donor derived MSCs (Fig. 2.2). The lack of oncogenic transformation in the 
presence of increasingly high frequencies of binucleate cells, suggests that cell cycle checkpoints 
were functionally intact, both in MSCs derived from OS patients and from healthy donors.
In addition to the functional read-out of long-term culture, we also performed gene expression 
analysis on early passage cells. Expression of HCLS1 was downregulated in MSCs from OS patients 
as compared to MSCs of healthy donors. HCLS1 is primarily known for its role in the signaling 
cascade that follows B cell receptor activation. It is highly expressed in B-cell derived malignancies 
and is associated with a poor outcome [75;233]. Further studies are needed to determine if HCLS1 
might have a tumor suppressor function and if its loss of expression in OS patients derived 
MSCs has any relationship to in vivo tumorigenesis.  Although we show no functional difference 
between healthy donor and OS patient derived MSCs, we do not advocate the use of MSCs from 
known cancer patients for clinical purposes. The relevance of the differential expression of HCLS1 
remains unknown and there might be other undetected (pre-) malignant alterations.
Both on a transcriptional and on a functional level, OS patient and healthy donor derived MSCs 
were very similar. There are several possible explanations for the observed similarities between 
OS patient derived and donor derived MSCs. First, we obtained MSCs from the iliac crest, while 
all tumors in our series were located at the metaphyseal ends of the long bones. OS occurs at a 
time and place of active growth and perhaps this pro-proliferative microenvironment (with high 
















Second, (pre-)oncogenic alterations may be present in only one or a few local mesenchymal 
tumor precursor cells and not in MSCs at a distant site such as the iliac crest. This could be due 
to somatic mosaicism, similar to what has been shown for the enchondromatosis syndromes 
Ollier disease and Maffucci syndrome [202]. Third, according to the ‘multiple hit hypothesis’, 
there may not have been sufficient ‘hits’ for in vitro transformation to occur, even if relevant 
predisposing alterations are present. Perhaps one or two additional ‘hits’ (for example loss of cell 
cycle checkpoint control) would be enough for oncogenic transformation to occur. Fourth, pre-
malignant alterations may have been present in only a few cells, which would not lead to large 
enough differences in gene expression to be picked up by genome wide expression analysis. 
Finally, although there is compelling evidence to suggest MSCs are the precursor cells for human 
OS, this has not yet been unequivocally proven. 
In conclusion, during long-term in vitro culture of human OS patient and healthy donor 
derived MSCs, oncogenic transformation did not occur. We could not confirm our hypothesis 
that MSCs of OS patients might have a higher propensity to oncogenic transformation than 
healthy donor derived MSCs. In contrast to what has been reported for other species, under the 
tested conditions, human MSCs do not easily transform. Therefore, administration of cultured 
human MSCs for therapeutic purposes is unlikely to result in sarcomas in the host. 
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Suppl. Fig. 2.1 Differentiation capacity and expression of membranous markers of MSCs. Representative examples 
are shown (40x magnification). a, chondrogenic differentiation was performed using cell pellet cultures and 
assessed using toluidine blue staining. Adipogenic differentiation was assessed using phase contrast microscopy 
(b) and Oil-red-O staining (c). Osteogenic differentiation was assessed using phase contrast microscopy (d) and 
Alizarin red staining (e). f, all samples expressed CD73, CD90 and CD105 (bold histograms) as determined by flow 
cytometry (isotype controle staining shown for comparison).
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ABSTRACT
INTRODUCTION: Resection of pulmonary metastases has previously been reported to improve 
outcome in high-grade osteosarcoma (OS) patients. Factors influencing survival in OS patients 
with pulmonary metastases are important for clinical decision making. METHODS: All 88 OS 
patients with pulmonary metastases either at diagnosis or during follow-up treated at the 
Leiden University Medical Center between January 1, 1990 and January 1, 2008 under the age of 
40 were included in this study, including 79 cases of conventional, eight cases of telangiectatic 
and one case of small cell OS. RESULTS: In total, 56 of 88 patients with pulmonary metastases 
were treated by metastasectomy. Resectability of pulmonary metastases was the main 
prognostic factor. In patients with primary non-metastatic OS, a longer relapse free interval to 
pulmonary metastases was significantly associated with better survival (P=0.02). Independent 
risk factors determining worse survival after metastasectomy in multivariate analysis were male 
sex (P=0.05), higher number of pulmonary nodules (P=0.03), and non-necrotic metastases 
(P=0.04). Whether surgery for recurrent pulmonary metastases was performed did not influence 
survival. Histological subtype of the primary tumor, histological response in the primary tumor 
after neoadjuvant chemotherapy, occurrence of local relapse, local resection or amputation 
of the primary tumor and age at diagnosis did not influence outcome. CONCLUSION: This 
cohort of patients with detailed follow-up data enabled us to identify important risk factors 
determining survival in OS patients with pulmonary metastases. We demonstrate that after 
repeated metastasectomies, a subset of patients can be cured.
INTRODUCTION
High-grade osteosarcoma (OS) is a malignant bone tumor mainly affecting adolescents and 
young adults [71]. Since the introduction of (neo-)adjuvant chemotherapy, long-term overall 
survival has improved to about 60%, with failure of therapy mainly attributed to chemoresistant 
metastatic disease. At diagnosis 15–25% of patients present with clinically detectable metastatic 
disease (synchronous pulmonary metastases) and about 40–50% of patients with primary 
non-metastatic disease experience relapse, mainly to the lungs (metachronous pulmonary 
metastases) [4;13;24;141;170;177;243].
Resection of pulmonary metastases with or without second-line chemotherapy has been 
reported to improve outcome in OS patients with pulmonary metastases and surgery is 
currently standard treatment in many institutions for patients in whom metastases are deemed 
resectable. Despite aggressive surgery, however, many patients still relapse. The two largest 
single-institution studies to date investigating prognostic factors determining survival of OS 
patients with lung metastases undergoing metastasectomy have had conflicting results. Studies 
conducted at the Rizzoli Institute concluded that higher numbers of pulmonary nodules, 
bilateral disease, and incomplete resection were independent prognostic factors for poor 
survival after metastasectomy [12;14;29]. This was confirmed in a large multi-center study and 
in several smaller studies [121;228;256;277]. In contrast, several studies concluded that neither 
number of pulmonary nodules nor other clinical parameters such as disease-free interval, 
bilateral disease or resection margins significantly affect survival [42;53;97]. In the subgroup 
of patients with metachronous disease, longer disease-free interval has been  associated with 
a favorable outcome, both in smaller single-center studies and in large multi-center studies 
[83;121;256;277]. The role of second-line chemotherapy is unclear, with only some authors 
describing a moderate survival benefit when administered in addition to metastasectomy [23]. 
In the current study, we sought to determine factors determining outcome in a cohort of 
patients with extensive follow-up data with high-grade OS metastasized to the lungs, including 
79 cases of conventional OS, eight cases of telangiectatic OS and one case of small cell OS.
PATIENTS AND METHODS
Definition of cohort
Between January 1990 and January 2008 197 patients under the age of 40 were treated for high-
grade OS at the Leiden University Medical Center. Excluded were patients with insufficient 
follow-up data (n=12) and unresectable primary tumor (n=11). Of the remaining 174 patients, 
all 88 patients who had pulmonary metastases either at diagnosis or during follow-up were 
included in this study (Table 3.1). Patients were treated according to one of the consecutive 
European Osteosarcoma Intergroup (EOI) trials 80861 [243] and 80931 [141] (doxorubicin 
and cisplatinum, with or without high-dose methotrexate, bleomycin, cyclophosphamide, 
actinomycin- D, and vincristin) or according to the Euramos-1 trial [1] (doxorubicin, cisplatinum, 




























Pulmonary metastases were diagnosed by routine computed tomography (CT) scans of the 
lungs and additional staging with 99mTc-bone scintigraphy, and if needed magnetic resonance 
imaging (MRI). Follow-up included clinical investigations and X-rays of the primary site and 
lungs. Number and distribution of pulmonary nodules were noted in case of suspected 
pulmonary metastases. 
Histopathology
Primary tumors were histologically classified according to the criteria of the World Health 
Organization [71]. Resected specimens of primary tumors were evaluated for histological response 
to neoadjuvant chemotherapy; good response was defined as less than 10% vital tumor tissue. 
Resected specimens of pulmonary metastases were evaluated for number of resected nodules 
and viability of resected tumor tissue. In addition, completeness of resection and occurrence of 
pleural contamination were noted on macroscopic and microscopic examination.
Statistical analysis
Unpaired t-tests, contingency analyses (χ2 method) and univariate survival analyses (Kaplan–
Meier method, log rank test for comparison of survival curves) were performed using GraphPad 
Prism 5.0. Multivariate survival analyses and survival analyses with continuous input variables 
were carried out according to the Cox proportional hazards model in SPSS version 16.0. Survival 
time was calculated from date of diagnosis to date of last follow-up or death (noted as overall 
survival) or from date of first metastatic event to date of last follow-up or death (noted as 
overall survival since metastasis). Two-sided P-values lower than 0.05 were determined to be 
significant; P-values between 0.05 and 0.10 were defined to be a trend.
RESULTS
Twenty-six of 88 patients had pulmonary metastases at diagnosis (synchronous pulmonary 
metastases, group A in Table 3.1) and 62 patients developed pulmonary metastases during follow-up 
(metachronous pulmonary metastases, group B in Table 3.1). The proportion of high-grade OS 
patients with clinically detectable pulmonary metastases did not change during the study period. 
About 15% of all high-grade OS patients had pulmonary metastases at diagnosis and 35% developed 
pulmonary metastases during follow-up. There was a male predominance in our cohort (71.6% males 
vs. 28.4% females) and there was a trend for males to have a worse overall survival (P logrank = 0.08). 
Most tumors were located in the distal femur (43/88, 48.9%), proximal tibia or fibula (18/88, 20.5%), 
and proximal humerus (8/88, 9.1%). Less frequently involved were the axial skeleton (5/88, 5.7%) or 
the other long bones (13/88, 14.8%). One tumor was located in the calcaneus. Histological subtype 
was conventional OS in 79 cases (including 17 chondroblastic, 2 fibroblastic and 6 unusual histological 
subtypes), telangiectatic OS in 8 cases and small cell OS in 1 case. 
There was no significant difference in overall survival (measured as survival since development 
of metastases to correct for time dependency of the variable) between patients with synchronous 
















metachronous lung metastases (group B) into three equal groups of 21 patients each based on 
the duration of the disease-free interval, longer disease-free interval was associated with better 
survival, with most deaths occurring in patients in the first tertile (metastasis from day 1 to day 310 
since diagnosis, Fig. 3.1) (P=0.02). Other factors associated with poor overall survival for patients 
with pulmonary metastases were higher numbers of pulmonary nodules as determined by CT 
scanning (9.3% increase in hazard for each additional pulmonary nodule, P=0.001) and bilateral 
involvement (P logrank=0.008). Patients with bone or other metastases present at the time of 
diagnosis of the pulmonary metastases had worse overall survival, mainly because in these cases, 
resection of metastases (pulmonary and others) was often not performed. Histological subtype, 
histological response to neo-adjuvant chemotherapy in the primary tumor (<10% viable tumor), 
location of the primary tumor, age at diagnosis, occurrence of local relapse and year of diagnosis 
did not affect survival in this cohort of patients with pulmonary metastasis.
Table 3.1 Overview of patients with pulmonary metastases of high grade osteosarcoma under age 40, treated 







No metastasectomy for pulmonary 
metastases (group 1)
1A, 5 (5.7%) 1B, 27 (30.7%) 32 (36.4%)
Metastasectomy for pulmonary 
metastases (group 2)
2A, 21 (23.9%) 2B, 35 (39.8%) 56 (63.6%)
Total 26 (29.5%) 62 (70.5%) 88
Fig. 3.1 Kaplan–Meier curve of patients with metachronous pulmonary metastases of osteosarcoma (group B), 
divided into three equal groups based on the duration of the disease-free interval (tertiles), demonstrating worse 



























Resection of pulmonary metastases
The majority of patients with pulmonary metastases were treated surgically for these metastases 
at least once (56/88, 63.6%). Overall survival of these patients (group 2) was significantly 
better than of patients ineligible for metastasectomy (group 1, Table 3.1 and Fig. 3.2, P<0.0001). 
Irresectability of disease as determined in multidisciplinary meetings including radiologists, 
pathologists, thoracic and orthopedic surgeons and clinical oncologists was the reason not to 
perform metastasectomy in most cases (81.3%) (Table 3.2). One patient with radiological evidence 
of lung metastases who did not undergo metastasectomy is a long-term survivor (duration of 
follow-up 18 years). In this patient, three pulmonary nodules appeared on CT-scanning 1 year 
after diagnosis of the primary tumor, ranging in size from 0.5 to 2 cm. The largest nodule had a 
high density, suggesting calcification. In the following year, lesions progressed in both size and 
number, after which the lesions stabilized without further treatment. All other patients with 
clinicoradiological evidence for lung metastases who did not undergo metastasectomy died. In 
these other cases with unresectable disease, no other curative treatments were available; some 
patients received palliative chemo- or radiotherapy.
Patients not undergoing metastasectomy for pulmonary metastases (group 2) had more 
nodules (mean of six vs. three, P=0.002), more often had bilateral disease (25% vs. 46%, χ2 P=0.06) 
and more often poor histological response to neo-adjuvant chemotherapy in the primary tumor 
(78% vs. 64%, χ2 P=0.05) than patients eligible for surgery (group 1). There was no difference in age.
Male sex, higher numbers of pulmonary metastases and viability 
of resected metastases are independent risk factors after surgical 
treatment of pulmonary metastases (group 2)
Although patients who were selected for pulmonary metastasectomy (group 2) had improved 
survival (Fig. 3.2), overall survival was still poor at about 23%. The majority of patients (30/56) 
underwent thoracotomy just once, but there was no significant survival difference for 
patients undergoing metastasectomy once or more often (P=0.29). This is also reflected in 
Fig. 3.3, which demonstrates the possibility of achieving complete remission after repeated 
metastasectomies. Males had surgery for metastases more often than females (70% vs. 48%, χ2 
Table 3.2 Reasons not to undergo surgical removal of pulmonary metastases
Number of patients (%) Reason not to undergo pulmonary metastasectomy
26/32 (81.3%) unresectable disease (including metastases to other sites (n=6) and rapidly 
progressive disease during neo-adjuvant chemotherapy (n=5))
1/32 (3.1%) died before metastasectomy could be performed
2/32 (6.3%) physical or mental condition of the patient did not allow it
1/32 (3.1%) unknown
2/32 (6.3%) regression of pulmonary metastasis during (neo-)adjuvant chemotherapy (one 
patient still alive after 18 years follow up, one patient had unresectable relapse in 
















P=0.05), but had worse overall survival (Fig. 3.4, P=0.04). Almost all of the patients with pleural 
disruption evident on histological examination or incomplete resection of the metastases 
in at least one of the metastasectomies died of disease, but this failed to reach significance 
(P=0.28). Twenty-nine patients (51.8%) had chemotherapeutic treatment before at least one 
of the metastasectomies. This chemotherapeutic treatment was given to patients either as 
a part of their primary (neo-) adjuvant treatment or to patients presenting with an initially 
unresectable pulmonary recurrence during followup. Nine patients had completely necrotic 
metastases removed at least once (as determined by histological examination) and there was 
a trend for better survival in these patients (P=0.09). Whether or not additional treatment was 
given before metastasectomy, did not influence survival, but there was an association between 
premetastasectomy treatment and subsequent removal of necrotic metastases (χ2 P=0.04).
As was the case in the entire cohort of patients with pulmonary metastases, higher numbers 
of metastases visible on CT scan prior to metastasectomy was associated with worse survival in 
group 2 patients (who underwent metastasectomy at least once, P=0.04). Similarly, there was a 
trend for patients with bilateral disease to have worse overall survival (P=0.07). However, 4 of 15 
patients with 5 or more nodules on CT scan did survive after resection of these lesions (follow-
up since first metastasis 18–38 months). There was a reasonable correlation between number of 
metastases as estimated by CT scan and the number of metastases found at metastasectomy (r2 
0.41, slope 0.7, P<0.0001), which did not change during the study period. Factors not associated 
with outcome were histological subtype of the primary tumor, histological response in the 
primary tumor to neo-adjuvant chemotherapy, occurrence of local relapse, local resection or 
amputation of the primary tumor and age at diagnosis. In contrast to analysis performed on 
the entire cohort of 88 patients, disease-free interval was not associated with prognosis in this 
subset of 56 patients who underwent surgery for pulmonary metastases.We used multivariate 
Fig. 3.2 Kaplan–Meier curve comparing overall survival of patients with pulmonary metastases treated surgically 
(group 1) and nonsurgically (group 2). Patients not treated surgically have a significantly worse overall survival 



























Cox regression analysis of risk factors in group 2 patients who underwent metastasectomy at 
least once, entering only variables with a P-value lower than 0.10 as determined by univariate 
analysis. This revealed male sex of the patient, higher numbers of pulmonary metastases and 
viability of resected metastases to be independent risk factors for worse outcome in pulmonary 
metastasized OS patients treated surgically (Table 3.3).
DISCUSSION
In this cohort of patients with pulmonary metastasized high-grade OS, 26/88 patients had 
clinically detectable pulmonary metastases at diagnosis (group A, Table 3.1) and 62/88 relapsed 
Fig. 3.3 Flow chart of all patients, demonstrating the possibility of achieving complete remission after repeated 
surgery for pulmonary metastases (including a patient who received surgery for pulmonary metastases four 
















with pulmonary metastases (group B). Metastasectomy was almost invariably required for cure, 
as has been previously described by others [12;97;121]. Since pulmonary metastasectomy is a 
safe and effective treatment, both in pediatric and adult patients, metastasectomy has become 
standard of care for patients with pulmonary metastasized OS when these metastases are 
deemed resectable and there are no other contra-indications for surgery (including metastasis 
to other sites) [261;269]. In our well-defined cohort of patients with detailed and extensive 
follow-up data we were able to confirm important risk factors determining survival in OS 
patients with pulmonary metastases, that is, extent of disease and longer disease-free interval. 
In addition, we have identified the novel independent risk factors male sex and resection of 
metastases containing viable tumor cells.
The administration of chemotherapeutic agents before metastasectomy is associated 
with a subsequent higher chance of resecting necrotic metastases, which in turn is associated 
with better overall survival. This would suggest a potential beneficial role of second-line 
chemotherapeutic agents in the treatment of metastasized OS, even when these lesions 
are deemed resectable. However, since we did not find a direct association between 
chemotherapeutic treatment and overall survival in the group of patients surgically treated 
Fig. 3.4 Kaplan–Meier curve of survival after metastasectomy (group 2 patients) for males (dashed line) versus females 
(solid line). Males had surgery for metastases more often than females (70% vs. 48%, χ2P=0.05), but had worse overall 
survival (P logrank=0.04, analysis on subgroup who underwent surgery for pulmonary metastatic disease).
Table 3.3 Multivariate Cox regression analysis to determine independent risk factors for survival in patients 
surgically treated for pulmonary metastasized high-grade osteosarcoma (group 2 patients)
Risk factor P-value Hazard ratio
Female sex 0.05 0.409
Completely necrotic metastases 0.03 0.167



























for pulmonary metastases, the addition of chemotherapy to the surgical treatment of patients 
with pulmonary metastases remains unproven. In previously published studies it has also been 
difficult to establish what the value of second-line chemotherapeutic treatment is to the surgical 
management of metastasized OS [23]. This could either mean that the true benefit is very small, 
or that the treatments employed are too heterogeneous to draw definite conclusions.
As was found in other studies, large metastatic tumor burden (defined as five or more 
pulmonary nodules or bilateral involvement), has prognostic relevance. It is now well known that 
spiral CT scanning (1mm slices) is more sensitive than conventional CT, allowing the detection 
of significantly larger number of nodules and also smaller nodules <5mm in diameter. Even these 
small pulmonary nodules should be regarded as probable pulmonary metastases when other 
risk factors for pulmonary nodules, such as smoking history or prior granulomatous disease, are 
absent. The proportion of patients diagnosed with pulmonary metastases in this study did not 
change during the study period.  Previously, Kayton et al. [120] reported that CT scanning of the 
chest underestimates the number of metastatic lesions in OS. In our cohort there was a reasonable 
correlation between number of metastases as predicted by CT scan and number of metastases 
as determined at resection. However, we feel that the presence of high numbers of pulmonary 
nodules should not guide decisions regarding resection if the nodules are resectable; a third of 
patients with high tumor burden, that is, five or more nodules onCT scan prior to surgery, survive 
after resection of the lesions with a median duration of follow-up of 25 months. Similarly, patients 
experiencing relapse after first metastasectomy can still benefit from repeated metastasectomies 
if these lesions are resectable and if there is no risk of respiratory compromise.
The reason for the relationship with gender and outcome in our cohort is unclear. There 
was a male predominance in our cohort (71.6% males vs. 28.4% females). Males had their 
metastases significantly more often surgically resected than females. However, men had lower 
overall survival even after resection of metastases. A recently published review of OS incidence 
and survival rates from 1973 to 2004 in the United States noted a worse overall survival for 
males over all age groups, concordant with previous smaller studies [177;205;227]. In another 
study, a strong correlation between male sex and poor histological response to pre-operative 
chemotherapy was found, although this did not result in worse overall survival [24]. OS cells 
express sex steroid receptors and it has been observed that 2-methoxyestradiol (2-ME), a 
naturally occurring metabolite of 17beta-estradiol (E2),  induces cell death in OS cells [57;155]. 
It remains unclear whether direct effects of sex steroids on neoplastic cells play a role in the 
observed better outcome for females, or if  other mechanisms are underlying this observation.
Patients with OS which has a good histological response of the primary tumor to neo-
adjuvant chemotherapy have better overall survival [98]. In our cohort of patients with OS 
and metastatic disease (group A and group B), there was no association between response to 
chemotherapy and survival. Similarly, the previously reported association of chondroblastic 
tumors with good histological response to chemotherapy and better overall survival, was not 
present in this cohort of patients with OS and lung metastasis. However, when analyzing all 
patients diagnosed with OS in our center, including those that did not develop pulmonary 
















also present in our cohort. This suggests that poor histological response to chemotherapy 
probably determines poor survival through risk of developing clinically detectable, pulmonary 
metastases. However, once these metastases have developed, the histological response in the 
primary tumor was no longer relevant in our series. 
Analysis of patients with resectable non-metastatic OS treated in three consecutive EOI 
trials demonstrated the association between early recurrence and poor survival [83]. In the 
current study, this association was also present in the subgroup of patients presenting with 
metachronous pulmonary metastases, but this association disappeared when patients eligible 
for surgical treatment of the metastases were selected. This indicates that patients presenting 
with relapse roughly within the first year after diagnosis have a higher chance of presenting 
with unresectable pulmonary involvement, but treatment of resectable pulmonary disease 
results in a similar outcome in this group.
In conclusion, this well-defined cohort of OS patients with pulmonary metastases treated 
within a single institution allowed us to establish that higher number of pulmonary nodules, 
resection of vital metastases and male sex were associated with poor overall survival. In the 
present study we confirm extent of disease, that is, number of pulmonary  nodules, to be 
an important independent risk factor determining survival in OS patients with pulmonary 
metastases. In addition we demonstrate that female sex and resection of necrotic metastases are 
associated with better survival after pulmonary metastasectomy. Importantly, we demonstrate 
that even after repeated metastasectomies, cure can be achieved in a subset of patients.
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ABSTRACT
PURPOSE: High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence 
in adolescence. Overall survival of patients with resectable metastatic disease is approximately 
twenty percent. The exact mechanisms of development of metastases in osteosarcoma 
remain unclear. Most studies focus on tumor cells, but it is increasingly evident that stroma 
plays an important role in tumorigenesis and metastasis. We investigated the development 
of metastasis by studying tumor cells and their stromal context. EXPERIMENTAL DESIGN: 
To identify gene signatures playing a role in metastasis, we performed genome-wide gene 
expression profiling on prechemotherapy biopsies of patients who did (n=34) and patients 
who did not (n=19) develop metastases within five years. Immunohistochemistry was 
performed on pre-treatment biopsies from two additional cohorts (n=63 and n=16), and on 
corresponding post-chemotherapy resections and metastases. RESULTS: 118/132 differentially 
expressed genes were upregulated in patients without metastases. Remarkably, almost half of 
these upregulated genes had immunological functions, particularly related to macrophages. 
Macrophage associated genes were expressed by infiltrating cells and not by osteosarcoma 
cells. Tumor-associated macrophages (TAMs) were quantified with immunohistochemistry 
and were associated with significantly better overall survival in the additional patient cohorts. 
Osteosarcoma samples contained both M1 (CD14/HLA-DRα positive) and M2 type TAMs (CD14/
CD163 positive and association with angiogenesis). CONCLUSION: In contrast to most other 
tumor types, TAMs are associated with reduced metastasis and improved survival in high-grade 
osteosarcoma. This study provides a biological rationale for the adjuvant treatment of high-
grade osteosarcoma patients with macrophage-activating agents, such as muramyl tripeptide.
INTRODUCTION
High-grade osteosarcoma is a malignant bone tumor characterized by the production of 
osteoid. The highest incidence is in adolescent patients, with a second peak in patients over 
40 years of age [214]. Despite wide-margin surgery and intensification of chemotherapeutic 
treatment, overall survival rates have reached a plateau at about sixty percent [13;24;141]. Novel 
treatment modalities are needed, but data on critical biological mechanisms allowing the 
development of novel therapeutic agents are scarce for this relatively rare tumor. In addition 
to conventional chemotherapeutic agents, recent trials have explored immunostimulatory 
strategies. The ongoing EURAMOS-1 trial randomizes for treatment with interferon (IFN)-α 
in patients with good histological response to neo-adjuvant chemotherapy [160]. A recently 
published clinical trial has shown improved overall survival for osteosarcoma patients treated 
with the macrophage activating agent muramyl tripeptide (MTP) added to the standard 
chemotherapy regimen [170]. However, only limited information on macrophage infiltration 
and activation in osteosarcoma is available [126].
Tumor-associated macrophages (TAMs) may promote tumorigenesis through 
immunosuppression, expression of matrix-degrading proteins and support of angiogenesis. In 
numerous cancer types, high numbers of M2 or ‘alternatively activated’ TAMs are associated 
with a worse prognosis [93;112;138;146;266;273]. M2 macrophages have important functions 
in wound-healing and angiogenesis, express high levels of the immunosuppressive cytokines 
IL-10 and TGF-β and express scavenger receptors such as CD163 [210;237]. ‘Classical activation’ 
of macrophages by interferon-γ or microbial products results in polarization towards M1 type 
macrophages. M1 macrophages express high levels of pro-inflammatory cytokines such as 
interleukin (IL)-12 , IL-1, and IL-6 and have potent anti-tumor efficacy, both by reactive oxygen 
species and cytokine-induced cytotoxicity and by induction of natural killer (NK) and T cell 
activity [188].  Rarely, high numbers of TAMs are associated with better prognosis [73;122]. In 
these cases, TAMs are presumably polarized towards an M1 phenotype, although macrophage 
subtypes were not reported in these two studies. Alternatively, macrophages may directly 
phagocytose tumor cells, as has been demonstrated in acute myeloid leukemia [109].
To investigate the role of stroma and stroma-tumor interactions important in metastasis 
of osteosarcoma, we investigated the development of metastasis by studying tumor cells 
and their stromal context. Using genome-wide expression analysis, we showed that high 
expression of macrophage-associated genes in pre-treatment biopsies was associated with a 
lower risk of developing metastases. In addition, we quantified and characterized TAMs in two 
independent cohorts, including pre-treatment biopsies, post-chemotherapy resections, and 
metastatic lesions. In contrast to the tumor-supporting role for TAMs in most epithelial tumor 
types, higher numbers of infiltrating TAMs correlated with better survival in osteosarcoma. 
Our findings suggest that macrophages have direct or indirect anti-osteosarcoma activity 
and provide a possible explanation for the beneficial effect of treatment with macrophage 

































Genome-wide expression profiling was performed on snap-frozen pre-treatment diagnostic 
biopsies containing viable tumor material of 53 resectable high-grade osteosarcoma 
patients from the EuroBoNet consortium (http://www.eurobonet.eu) (cohort 1). For 
immunohistochemical validation a tissue microarray containing 145 formalin-fixed paraffin-
embedded (FFPE) samples of 88 consecutive high-grade osteosarcoma patients with primary 
resectable disease (cohort 2) and 29 FFPE samples of a cohort of 20 consecutive high-grade 
osteosarcoma patients with resectable disease were used (cohort 3), including material 
from pre-treatment biopsies, postchemotherapy resections, and metastatic lesions [183]. 
Clinicopathological details can be found in Suppl. Table 4.1. All biological material was handled 
in a coded fashion. Ethical guidelines of the individual European partners were followed and 
samples and clinical data were stored in the EuroBoNet biobank.
Cell lines
The nineteen osteosarcoma cell lines HAL, HOS, HOS-143b, IOR/MOS,IOR/OS10, IOR/OS14, IOR/
OS15, IOR/OS18, IOR/OS9, KPD, MG-63, MHM,MNNG-HOS, OHS, OSA, Saos-2, SARG, U2OS, and 
ZK-58 were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal 
calf serum and 1% Penicillin/Streptomycin (Invitrogen) as previously described [199]. 
RNA isolation, cDNA synthesis, cRNA amplification, and Illumina 
Human-6 v2.0 Expression BeadChip hybridization
Osteosarcoma tissue was snap-frozen in 2-Methylbutane (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) and stored at -70°C. Using a cryostat, 20 μm sections from each block were cut 
and stained with hematoxylin and eosin to ensure at least 70% tumor content and viability. RNA 
was isolated using TRIzol (Invitrogen), followed by RNA clean-up using the QIAGEN Rneasy mini 
kit with on-column DNAse treatment (Venlo, the Netherlands). RNA quality and concentration 
were measured using an Agilent 2100 Bioanalyzer (Santa Clara,CA, USA) and Nanodrop 
ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA), respectively. Synthesis of cDNA, cRNA 
amplification, and hybridization of cRNA onto the Illumina Human-6 v2.0 Expression BeadChips 
(San Diego, CA, USA) were performed as per manufacturer’s instructions. Reverse transcriptase 
quantative polymerase chain reaction (RT-qPCR) RT-qPCR analysis of selected target genes was 
performed as previously described [220]. Each experiment was performed in duplicate using 
an Automated Liquid-Handling System (Tecan, Genesis RSP 100, Männedorf, Switzerland). 
Data were normalized using geometric mean expression levels of three reference genes, i.e. 
SRPR, CAPNS1, and TBP using geNorm (http://medgen.ugent.be/~jvdesomp/genorm/). Primer 
sequences can be found in Suppl. Table 4.2.
Enzymatic and fluorescent immunostainings
Enzymatic and fluorescent immunostainings were performed on 4 μm sections of FFPE tissue 
















Suppl. Table 4.3. In case of double immunohistochemistry (IHC), incubation with anti-CD45 
and development with DAB+ (Dako, Glostrup, Denmark) occurred first, followed by a second 
antigen retrieval before incubation with either anti-CD163 or anti-HLA-DRα and development 
using the alkaline-phosphatase substrate Vector Blue (Vector Labs, Burlingam, CA, USA). In case 
of double immunofluorescent (IF) stainings, primary antibodies were co-incubated overnight. 
As a positive control normal and formic acid decalcified tonsil was used, as a negative control 
no primary antibody was added. Tissue microarray slides were scanned using the MIRAX SCAN 
slide scanner and software (Zeiss, Mirax 3D Histech, Hungary). Numbers of positively stained cells 
and vessels were counted using ImageJ (National Institutes of Health, Bethesda, Maryland, USA) 
and averaged per 0.6 mm core. IF and double IHC images were acquired using a Leica DM4000B 
microscope (Wetzlar, Germany) fitted with a CRI Nuance spectral analyzer (Cambridge Research 
and Instrumentation Inc., Woburn, MA, USA) and analyzed using the supplied co-localization tool 
to determine percentage of single and double positive pixels per region of interest.
Microarray data analysis
Gene expression data were exported from BeadStudio version 3.1.3.0 (Illumina) in GeneSpring 
probe profile format and processed and analyzed using the statistical language R [211]. As Illumina 
identifiers are not stable and consistent between different chip versions, raw oligonucleotide 
sequences were converted to nuIDs [59]. Data were transformed using the variance stabilizing 
transformation algorithm to take advantage of the large number of technical replicates 
available on the Illumina BeadChips [145]. Transformed data were normalized using robust 
spline normalization, an algorithm combining features of quantile and loess normalization, 
specifically designed to normalize variance stabilized data. All microarray data processing was 
carried out using Bioconductor package lumi [60;84]. Quality control was performed using 
Bioconductor package arrayQualityMetrics [119]. MIAME-compliant data have been deposited 
in the GEO database  (www.ncbi.nlm.nih.gov/geo/, accession number GSE21257).
Statistical analysis
Differential expression between patients who did (n=34) and did not (n=19) develop metastases 
within five years from diagnosis of the primary tumor was determined using Linear Models 
for Microarray Data (LIMMA),[240] applying a Benjamini and Hochberg False Discovery Rate 
adjusted P-value cut-off of 0.05. Other univariate statistical analyses were performed using 
GraphPad Prism software (version 5.01, La Jolla, California, USA). Multivariate survival analyses 
were carried out according to the Cox proportional hazards model in SPSS (version 16.0.2, 
Chicago, Illinois, USA). Two-sided P-values <0.05 were determined to be significant; P-values 
































High expression of macrophage-associated genes in osteosarcoma 
biopsies of patients who did not develop metastases within five years 
from diagnosis (cohort 1) 
Comparison of genome-wide gene expression in tumors of patients who did and did not 
develop metastases within five years resulted in 139 significantly differentially expressed (DE) 
probes, of which 125 corresponded to 118 upregulated and 14 to downregulated genes in 
patients who did not develop metastases. A summary of DE genes and detailed descriptions 
of all probes can be found in Table 4.1 and Suppl. Table 4.4, respectively. Two DE genes were 
specific for macrophages (CD14 and MSR1) and 30/132 of the DE genes were associated with 
macrophage functions such as antigen processing and presentation (e.g. HLA-DRA and CD74) 
or pattern recognition (e.g. TLR4 and NLRP3). Overall, approximately 20% of the upregulated 
probes corresponded to genes which were associated with macrophage function and 
development and an additional 25% of the upregulated probes corresponded to genes with 
other immunological functions, such as cytokine production and phagocytosis. Four genes 
were selected for validation of the microarray data using RT-qPCR: CD14, HLA-DRA, CLEC5A, 
and FCGR2A. Expression levels as determined by RTqPCR correlated well with expression levels 
obtained by microarray analysis (Suppl. Fig. 4.1). Metastases-free survival curves of the same 
cohort, generated using median expression of the probe of interest as a cut-off determining 
low and high expression, are shown in Fig. 4.1b and in Suppl. Fig. 4.2. Cox proportional hazards 
analysis revealed expression of macrophage-associated genes CD14 and HLA-DRA to be 
independently associated with metastasis free survival (Suppl. Table 4.5). 
Macrophage-associated genes are expressed by infiltrating 
hematopoietic cells and not by tumor cells
The most probable source of expression of the differentially expressed macrophage-associated 
genes were infiltrating immune cells and not osteosarcoma cells. To confirm this, we performed 
qRT-PCR of CD14 and HLA-DRA on osteosarcoma cell lines (n=19) and biopsies (n=45, a subset 
of cohort 1). CD14 and HLA-DRA expression was variable in osteosarcoma biopsies, but 
almost undetectable in cell lines. This indicates that these macrophage-associated genes 
were not expressed by tumor cells but by infiltrating cells, since only osteosarcoma biopsies 
contain macrophage infiltrate, whereas RNA from cell lines is exclusively from tumor cells 
(Fig. 4.1a, P-value Mann-Whitney U test <0.0001). In addition, we performed double IHC for 
the hematopoietic cell marker CD45, which is not expressed by osteosarcoma tumor cells, and 
the macrophage marker CD163 or the macrophage-associated protein HLA-DRα (Fig. 4.1c). We 
chose this approach because no reliable osteosarcoma markers are available (1). Our results 
confirmed that infiltrating, hematopoietic cells were the source of the macrophage-associated 
gene expression levels. Together, these data show that osteosarcoma tumor cells do not 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4.1 Macrophage-associated genes are not expressed by osteosarcoma tumor cells. a, RT-qPCR of 
osteosarcoma cell lines and biopsies of CD14 and HLA-DRA demonstrating lack of expression by osteosarcoma 
cells. P-value Mann-Whitney U test <0.0001 noted as ***.  b, high expression of macrophage associated 
genes was associated with a better metastasis-free survival (cohort 1, Kaplan-Meier curve, P-value obtained 
using logrank test, patients with metastasis at diagnosis have an event at t=0. These patients are included, 
because patients who develop metastases later on may as well have micrometastases at time of diagnosis. 
Metastasis-free survival curves for HLA-DRA, CLEC5A, and FCGR2A can be found in Supplemental Figure 2. 
c, double immunohistochemical staining of CD163 with the hematopoietic cell marker CD45 was performed 
with haematoxylin counterstain (H) and analyzed using spectral imaging microscopy. The pseudo-
immunofluorescent image (pseudo-IF) shows CD163 positive cells in red, CD45 positive cells in green and co-
localization of both markers in orange. Lack of expression of CD163 and CD45 on surrounding tumor cells (dark 
















Macrophage numbers in osteosarcoma biopsies correlate with  
CD14  gene expression levels and are positively associated with 
localized disease and better outcome (cohorts 2 and 3)
To confirm the presence of TAMs in osteosarcoma we stained a tissue microarray containing 145 
samples of 88 patients for the macrophage marker CD14 and counted the number of positive 
cells per tissue microarray core (cohort 2, Fig. 4.2a). CD14 was chosen as opposed to CD68 
because the latter marker is not expressed by monocytes and often shows cross-reactivity with 
mesenchymal tissue (data not shown). Number of CD14 positive cells per tissue microarray 
core correlated significantly with CD14 mRNA expression levels (14 samples overlap with gene 
expression analysis, Spearman correlation coefficient 0.64, P-value = 0.01). Similar to the gene 
expression data, there was a trend for patients with primary localized disease to have higher 
numbers of macrophages in pre-treatment diagnostic biopsies than patients with metastatic 
disease at presentation (mean number of macrophages per core 55 vs. 27, Mann-Whitney U 
test P-value 0.09). Also, patients with high macrophage counts at diagnosis tended to be less 
likely to develop metastases within five years (χ² P-value 0.13). We subdivided this cohort into 
four quartiles based on numbers of CD14 positive cells in order to determine the group with 
the best overall survival. No significant differences were found between quartiles 2-4, but 
patients beloning to this group had better overall survival as compared to patients with low 
CD14 counts (lowest quartile, or less than 12 CD14 positive cells per tissue array core, Fig. 4.2b, 
P-value log-rank test = 0.02). In another cohort of 16 patients, IF staining of CD14, CD163 and 
HLA-DRα was performed, again confirming a potential prognostic value of high macrophage 
numbers (cohort 3, Fig. 4.3, P-value log-rank test = 0.01 and Suppl. Fig. 4.3).
Macrophages in osteosarcoma have both M1 and M2 characteristics
To determine the phenotype of macrophages present in osteosarcoma, we performed 
double IHC with CD14 and either the M1-associated marker HLA-DRα or the M2-associated 
marker CD163. Not all CD163 and HLA-DR positive infiltrating cells expressed CD14 (Fig. 4.3a 
and Suppl. Fig. 4.3a). The total number of macrophages as determined by quantifying CD14 
positive macrophages was associated with good survival (Fig. 4.3b), but the phenotype of the 
macrophages (CD14/CD163 double positive versus CD14/HLA-DRα double positive) was not 
(Suppl. Fig. 4.3b and data not shown). Another M2 characteristic is support of angiogenesis. 
The number of CD14 positive macrophages correlated with the number of CD31 positive vessels 
(Fig. 4.2a and Fig. 4.4), but vascularity did not correlate with prognosis (data not shown).
Macrophage numbers in diagnostic biopsies may predict histological 
response to chemotherapy and macrophage number increases 
following chemotherapy treatment
There was a trend for high macrophage count (highest three quartiles or >12 CD14-positive 
cells per tissue array core) in pre-chemotherapy diagnostic biopsies of the primary tumor to 
predict for good histological response to neoadjuvant chemotherapy (defined as more than 




































Fig. 4.2 a, example of representative stainings of high-grade osteosarcoma with high (left panels) versus low 
(right panels) levels of macrophage infiltration (CD14 staining) and vascular density (CD31 staining). b, high 
numbers of infiltrating macrophages (left panel, defined as the three upper quartiles, or more than twelve CD14 
positive cells per tissue array core) are associated with better overall survival (right panel, P-value logrank test = 
0.02, cohort 2). Q1, lowest quartile; Q2, 3, 4, three highest quartiles.
numbers and 18% of patients with low macrophage numbers had a good histological response 
(cohort 2; χ² P-value 0.09). The prognostic benefit of macrophage counts in osteosarcoma was 
not independent of histological response using Cox proportional hazard analysis. Macrophage 
numbers were higher in post-chemotherapy resections of the primary tumor as compared to 
the pre-chemotherapy biopsies (Suppl. Fig. 4.4). Moreover, gene expression analysis showed 
upregulation of macrophage-associated probes in post-chemotherapy resections (n=4) as 
















Fig. 4.3 a, osteosarcoma samples are infiltrated with CD14 and CD163 single and double positive macrophages. 
Spectral imaging was used to reduce auto-fluorescence of osteosarcoma cells. In the composite image, 
CD14 positive cells are represented in green, CD163 positive cells are represented in red, and CD14/CD163 
double positive cells are represented in yellow. Background auto-fluorescence of tumor cells is represented 
in grey. b, in an independent cohort of 16 patients (cohort 3), high macrophage infiltration as determined by 
immunofluorescent CD14 staining was associated with significantly improved overall survival. P-values obtained 
using logrank test, cut-off at the median.
DISCUSSION
Overall survival of high-grade osteosarcoma patients with resectable metastatic disease is poor at 
about twenty percent [32]. Mechanisms for the development of metastases in osteosarcoma are 
elusive. To identify genes that play a role in this process, we performed genome-wide expression 
profiling on pre-chemotherapy biopsies of osteosarcoma patients. We compared patients who 
developed clinically detectable metastases within five years with patients who did not develop 





















































Fig. 4.4 Macrophage infiltration as determined by CD14 positive cell count correlated with vascularity as 
determined by CD31 positive vessel count. Data of all osteosarcoma samples (pre- and post-treatment primary 
tumor and metastatic samples, cohort 2) is shown. Q1, lowest quartile; Q2, 3, 4, three highest quartiles. Kruskal-
Wallis test P < 0.0001, Dunn’s post-test P-values <0.05 noted as *, <0.001 noted as ***.
patients without metastases were macrophage-associated, while an additional 25% percent of 
genes had other immunological functions (for example in phagocytosis, complement activation 
or cytokine production and response) but could still be attributed to macrophages (Table 4.1 
and Suppl. Table 4.4). Thus, in total almost half of the differentially expressed genes belonged to 
one specific process, i.e. macrophage function. Macrophage-associated genes were expressed 
by infiltrating hematopoietic cells and not by osteosarcoma tumor cells (Fig. 4.1), indicating 
a possible role for macrophages in preventing metastasis in osteosarcoma. To confirm these 
findings, we quantified infiltrating macrophages in two additional cohorts (cohort 2 and 3) and 
found an association with better overall survival in both cohorts.
The anti-metastatic effect of TAMs in osteosarcoma is remarkable, since TAMs support 
tumor growth in a substantial number of other cancers, which are mostly tumors of epithelial 
origin. For example, macrophages are associated with the angiogenic switch in breast cancer 
[144]. We find an association between macrophage infiltration and higher microvessel density, 
which suggests that the influx of macrophages may support certain aspects of tumor growth 
in osteosarcoma as well. However, in the case of osteosarcoma, direct or indirect anti-tumor 
activity of macrophages apparently outweighs their possible tumor-supporting effects. 
Macrophages can alter their phenotype from M2 to M1 and become the tumor’s foe instead 
of its friend, given the right circumstances [35;92;239]. The TAMs that were identified in this 
study in osteosarcoma had both M1 and M2 characteristics. The expression of CD163 and 
the association with angiogenesis are M2 characteristics [144;195]. Some of the differentially 
expressed genes, such as MSR1 and MS4A6A are specific for M2 macrophages in vitro [161]. 
















[188]. How macrophages inhibit osteosarcoma metastasis and if a balance between M1 and M2 
type functions is responsible, is unknown.
In a multivariate regression model, the survival benefit of high TAM numbers was at least partly 
dependent on histological response to chemotherapy. Chemotherapy can cause “immunogenic 
cell death” of cancer cells, resulting in the release of endogenous danger signals [129;288]. The 
binding of these danger signals to pattern recognition receptors on macrophages can skew 
polarization of M2 to M1 type TAMs. The interaction between dying tumor cells and resident 
TAMs may facilitate clearance or inhibit outgrowth of metastatic tumor cells. However, patients 
with localized disease at diagnosis tended to have a larger macrophage infiltrate than patients 
with metastatic disease at diagnosis (mean number of macrophages per core 55 vs. 27). At this 
point, patients have not undergone chemotherapeutic treatment yet and an interaction between 
chemotherapy and macrophages can therefore not be responsible for the anti-metastatic 
effect of macrophages. Perhaps the anti-metastatic effect of TAMs in these patients is due to 
the constitutive presence of macrophages with an M1 phenotype. Alternatively, the presence 
of macrophages might be a reflection of a microenvironment not conducive for metastasis. 
Although preliminary analysis of a clinical trial investigating the effect of treatment with the 
macrophage activating agent MTP yielded conflicting results, subsequent analysis revealed that 
treatment with MTP improved six-year overall survival from 70 to 78% in a cohort of patients 
with primary localized disease [169;170]. Similar results were obtained in canine osteosarcoma 
[134]. MTP is a synthetic derivative of muramyl dipeptide (MDP), a common bacterial cell wall 
component. Muropeptides bind to intracellular pattern recognition receptors of the nucleotide-
binding and oligomerization domain (NOD) like (NLR) family, expressed by macrophages [82]. 
In our study, five genes associated with NLR family signaling and the associated ‘inflammasome’ 
were highly expressed in pre-treatment biopsies of patients who do not develop metastases. 
The differentially expressed genes NLRP3, NAIP, NLRC4 and PYCARD are components of the 
inflammasome, LYZ is a lysozyme which processes bacterial cell wall peptidoglycan into muramyl 
dipeptide, a ubiquitous natural analogue of MTP and IL1B is the downstream effector cytokine 
of the inflammasome pathway. Further research is needed to clarify if only patients with high 
numbers of TAMs benefit from MTP treatment, or if MTP treatment is effective regardless of 
macrophage number or activation status pre-treatment. Also, it is unknown if treatment with 
agents promoting macrophage migration or with other macrophage activating agents like 
toll-like receptor ligands or interferons have a similar beneficial effect on outcome. 
Previous genome-wide expression profiling studies in osteosarcoma focused on identifying 
genes that predict histological response to neo-adjuvant chemotherapy [153;176;194;229]. As a 
consequence, the importance of macrophages in controlling metastases was not recognized. 
However, we previously compared gene expression profiles of osteosarcoma biopsies and 
cultured mesenchymal stem cells and determined which genes are expressed by tumor stroma 
and not by tumor cells [47]. There is considerable overlap between the stromal genes identified 
in our previous study and the macrophage-associated genes identified in the present study 
(including HLA class II genes as the most prevalent differentially expressed group of genes and 































In conclusion, we demonstrated the presence and clinical significance of TAMs in pre-
treatment samples of high-grade osteosarcoma. TAMs in osteosarcoma are a heterogeneous 
cell population with both M1 anti-tumor and M2 pro-tumor characteristics. Although the exact 
mechanism by which macrophages exert their anti-metastatic functions is still unknown, this 
study provides an important biological rationale for the treatment of osteosarcoma patients 
with macrophage activating agents.
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Suppl. Fig. 4.2 High levels of HLA-DRA, CLEC5A and FCGR2A as determined using genome-wide expression 
profiling was associated with significantly improved metastases free survival. P-values obtained using logrank 
















Suppl. Fig. 4.3 a, osteosarcoma samples are infiltrated with CD14 and HLA-DRα single and double positive 
macrophages. Spectral imaging was used to reduce auto-fluorescence of osteosarcoma cells. In the composite 
image, CD14 positive cells are represented in green, HLA-DRα positive cells are represented in red, and CD14/
HLA-DRα double positive cells are represented in yellow. Background auto-fluorescence of tumor cells is 
represented in grey. b, in 16 patients treated according to the EURAMOS-1 protocol (cohort 3), there was a trend 
for high macrophage infiltration as determined by immunofluorescent HLA-DRα and CD163 to be associated with 




























































Suppl. Fig. 4.4 In post-chemotherapy samples, macrophage numbers increased (post-chemotherapy resections 
of the primary tumor vs. pre-treatment diagnostic biopsies, cohort 2). Kruskal-Wallis test P-value = 0.0094, 
















Suppl. Table 4.1 Clinicopathological data of osteosarcoma samples and patient characteristics. Treatment 
regimens containing high-dose methotrexate (M), doxorubicin (A), cisplatin (P) and/or ifosfamide (I) were used.
Patient characteristics Cohort 1 Cohort 2 Cohort 3
Samples used for: Microarray analysis Tissue microarray: CD14 
and CD31 staining
Immunofluorescent staining 
of CD14, CD163, HLA-DRα
Total nr of samples 53 (of 53 patients) 145 (of 88 patients) 29 (of 20 patients)
pre-treatment biopsies  
of primary tumor
53 (of 53 patients) 73 (of 73 patients) 16 (of 16 patients)
post-chemotherapy resections  
of primary tumor
0 45 (of 45 patients) 13 (of 13 patients)
metastatic lesions 0 24 (of 15 patients) 0
Year of diagnosis 1986-2006 1984-2003 2007-2008
Institution      
LUMC, Netherlands 27 all all
IOR, Italy 7    
LOH, Sweden 2    
Radiumhospitalet, Norway 1    
WWUM, Germany 16    
Treatment regimens MAPI, MAP, PIA, AP AP, PIA MAP
Location of primary tumor n (%) n (%) n (%)
Femur 27 (50.1) 45 (51.1) 18(62.1)
Tibia/fibula 17 (32.1) 31 (35.2) 6 (20.7)
Humerus 8 (15.1) 10 (11.4) 5 (17.2)
Axial skeleton 0 (0) 1 (1.1) 0 (0)
Hand 0 (0) 1 (1.1) 0 (0)
Unknown/ other 1 (1.9) 0 (0) 1 (3.4)
Histological subtype      
Conventional osteosarcoma      
- osteoblastic 32 (60.4) 59 (67.0) 19 (65.5)
- chondroblastic 6 (11.3) 9 (10.2) 3 (10.3)
- fibroblastic 5 (9.4) 3 (3.4) 1 (3.4)
- unusual 7 (13.2) 8 (9.1) 2 (6.9)
Telangiectatic 3 (5.7) 6 (6.8) 4 (13.8)
High grade surface osteosarcoma 0 (0) 1 (1.1) 0 (0)
Small cell osteosarcoma 0 (0) 2 (2.3) 0 (0)
Histological response to pre-operative chemotherapy in the primary tumor 
Unknown 6 (11.3) 12 (13.6) 1 (3.4)
Poor response 29 (54.7) 48 (54.5) 15 (51.7)
Good response 18 (34.0) 28 (31.8) 13 (44.8)
Sex      































Suppl. Table 4.2 RT-qPCR primer sequences. These sequences have been submitted to the Real Time PCR Primer 
and Probe Database (http://medgen.ugent.be/rtprimerdb/). All PCR products were validated by sequencing.
Gene symbol Product size (bp) Forward primer sequence (5’-3’) Reverse primer sequence (5’-3’)
CD14 198 GCCGCTGTGTAGGAAAGAAG AGGTTCGGAGAAGTTGCAGA
CLEC5A 128 GGCGTTGGATCAACAACTCT GATCCTGCGGTAGCTGATGT
FCGR2A 80 TATGTCCCAGAAACCTGTGG GGGAGCAGCTTGACTGTCTG
HLA-DRA 141 TGTAAGGCACATGGAGGTGA ATAGGGCTGGAAAATGCTGA
Suppl. Table 4.3  Antibodies and conditions used for immunohistochemistry and immunofluorescence.
Antibody Clone/ catalogue nr Company Methods
CD31 Ab-1, clone JC/70A Neomarkers Fremont, CA, USA Antigen retrieval (AR): 1 mM EDTA 
solution (pH 8.0). Secondary antibody 
(2nd ab): Envision Horse Radish 
Peroxidase (HRP) anti-mouse (Dako), 
chromogen DAB+ (Dako, K3468)
CD14 Ab-2, clone 7 Neomarkers AR: 10mM Tris/ 1 mM EDTA (pH 9.0). 
2nd ab: Envision anti-mouse HRP (Dako) 
followed by DAB+; Alexa Fluor-488 goat 
anti-mouse IgG2a (Invitrogen)
CD163 NCL-CD163 Novocastra, Newcastle Upon 
Tyne, England
AR: 10mM Tris/ 1 mM EDTA (pH 9.0). 
2nd ab: Envision anti-mouse HRP (Dako) 
followed by DAB+; Goat-anti-mouse 
alkaline phosphatase (AP) (Dako, nr) 
followed by Vector Blue (Vector Labs); 
Alexa Fluor-647 goat anti-mouse IgG1 
(Invitrogen)
HLA-DRα TAL.1B5 Dako AR: 10mM Tris/ 1 mM EDTA (pH 9.0).2nd 
ab: Envision anti-mouse HRP (Dako) 
followed by DAB+; Goat-anti-mouse 
(AP) (Dako) followed by Vector Blue; 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chemotherapy resistant osteosarcoma 
is highly susceptible to IL-15 activated 
allogeneic and autologous NK cells
Emilie P. Buddingh, Marco W. Schilham, S. Eriaty N. Ruslan,  
Dagmar Berghuis, Karoly Szuhai, Jolien Suurmond, 
Antonie H.M. Taminiau, Hans Gelderblom, R. Maarten Egeler, 
Massimo Serra, Pancras C.W. Hogendoorn, Arjan C. Lankester
Cancer Immunol Immunother. 2011 Apr;60(4):575-86.
ABSTRACT
INTRODUCTION: High-grade osteosarcoma occurs predominantly in adolescents and young 
adults and has an overall survival-rate of about 60%, despite chemotherapy and surgery. 
Therefore, novel treatment modalities are needed to prevent or treat recurrent disease. 
Natural killer (NK) cells are lymphocytes with cytotoxic activity towards virus infected or 
malignant cells. We explored the feasibility of autologous and allogeneic NK cell mediated 
therapies for chemotherapy resistant and sensitive high-grade osteosarcoma. METHODS: The 
expression by osteosarcoma cells of ligands for activating NK cell receptors was studied in vitro 
and in vivo and their contribution to NK cell mediated cytolysis was studied by specific antibody 
blockade. RESULTS: Chromium release cytotoxicity assays revealed chemotherapy sensitive 
and resistant osteosarcoma cell lines and osteosarcoma primary cultures to be sensitive to NK 
cell mediated cytolysis. Cytolytic activity was strongly enhanced by IL-15 activation and was 
dependent on DNAM-1 and NKG2D pathways. Autologous and allogeneic activated NK cells 
lysed osteosarcoma primary cultures equally well. Osteosarcoma patient derived NK cells were 
functionally and phenotypically unimpaired. CONCLUSION: In conclusion, osteosarcoma cells, 
including chemoresistant variants, are highly susceptible to lysis by IL-15-induced NK cells from 
both allogeneic and autologous origin. Our data support the exploitation of NK cells or NK cell 
activating agents in patients with high-grade osteosarcoma.
INTRODUCTION
High-grade osteosarcoma is the most common primary malignant bone sarcoma, occurring 
mainly in adolescents and young adults [125]. Despite multi-agent chemotherapy and surgery, 
overall survival is still poor at about sixty percent [24;32;141]. Therefore, novel treatment 
modalities are urgently needed to either prevent or treat chemotherapy refractory and 
recurrent disease. Immunomodulatory agents such as interferon (IFN)-α and muramyl-tri-
peptide (MTP) have been added to standard chemotherapy regimens in recent clinical trials 
[160;169;170].  Immunotherapy with stimulatory cytokines such as IL-2 and IL-15, or the adoptive 
transfer of ex vivo cytokine activated cytotoxic lymphocytes such as natural killer (NK) cells 
could be another adjunct to current therapy [148;174;255].
NK cells lack a clonally rearranged antigen-specific receptor. Instead, cytolytic activity towards 
virus infected or malignant cells is dependent on the balance between inhibitory and activating 
signals. NK cell activating signals are provided when the activating receptors Natural Killer Group 
2, member D (NKG2D), DNAX accessory molecule-1 (DNAM-1) and the natural cytotoxicity 
receptors (NCRs) NKp30, NKp44 and NKp46 bind their respective ligands [178;186;272]. Although 
NK cell recognition of tumor cells has been reported to be partially mediated through NCRs, the 
responsible ligands are unknown [135]. The DNAM-1 ligands poliovirus receptor (PVR, CD155) 
and Nectin-2 (CD112) are highly expressed by many tumors, including sarcomas [26;64;272]. 
Ligands for NKG2D are the stress-inducible major histocompatibility class I polypeptide-related 
sequence (MIC) A and B and the UL-16 binding proteins (ULBPs) 1 to 4. Inhibitory ligands are 
the classical and non-classical human leukocyte antigen (HLA) class I molecules expressed 
on all normal cells [118]. These ligands bind to inhibitory killer immunoglobulin-like receptors 
(KIRs) and the C-type lectin heterodimer CD94/NKG2A on NK cells, respectively. In addition to 
high expression of NKG2D and DNAM-1 ligands, many tumors show loss of HLA class I, possibly 
rendering them susceptible to NK cell mediated lysis [20;38].
In the current study, we demonstrated the sensitivity of chemotherapy resistant and 
sensitive osteosarcoma cells to lysis by IL-15 activated NK cells and identified the molecular 
mechanisms involved. NK cells of osteosarcoma patients were not functionally impaired and 
were able to lyse autologous tumor cells, supporting the use of NK cell activating agents in the 
treatment of osteosarcoma patients.
MATERIALS AND METHODS
Patient material
A tissue array was constructed from formalin fixed, paraffin embedded (FFPE) tissue 
retrospectively collected from 88 osteosarcoma patients treated at the LUMC as previously 
described [183] (Suppl. Table 5.1). Peripheral blood mononuclear cells (PBMCs) were 
collected from healthy controls and 22 pre-treatment osteosarcoma patients after written 
informed consent was obtained, as approved by the Institutional Review Board on Medical 
Ethics. Osteosarcoma tissue samples were used for research in accordance with national 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Medical Scientific Societies). All patient material was handled in a coded fashion. Clinical and 
pathological details of all patients can be found in Suppl. Table 5.2.
Cell lines and primary cultures
The osteosarcoma cell lines HOS, 143B/HOS, IOR-OS14, SJSA-1, OHS, ZK-58, U2-OS and SAOS-2 
were characterized and maintained as described earlier [199]. The EBV B-LCL cell line 107 (EBV) 
and the erythroleukemic cell line K562 were maintained in RPMI 1640 medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal calf serum (FCS, Invitrogen) and 1% penicillin/
streptomycin (PS, Invitrogen). The chemotherapy resistant variant cell lines of U2-OS and 
SAOS-2 were established as described previously [204;235;236] and were maintained in Iscove’s 
Modified Dulbecco’s Medium (IMDM, Invitrogen) supplemented with 10% FCS and PS. The 
doxorubicin (DX) resistant variants U2-OS-DX580 and SAOS-2-DX580 were cultured in the 
presence of 580 μg/mL DX. The methotrexate (MTX) resistant variants U2-OS-MTX300 and 
SAOS-2-MTX1μg were cultured in the presence of 300 and 1000 ng/mL MTX, respectively. The 
cisplatin (cis-diamminedichloroplatinum, CDDP) resistant variants U2-OS-CDDP4μg and SAOS-
2CDDP6μg were cultured in the presence of 4 and 6 μg/mL CDDP respectively.
Fresh osteosarcoma samples L2808, L2599, L2792, L2635 and L2531 were cultured as described 
previously by our group for related tumors [252]. Clinical and histopathological details can be 
found in Suppl. Table 5.3. L2531, L2792 and L2599 were derived from patients with poor histological 
response to pre-operative chemotherapy in the primary tumor. L2808, a pulmonary metastatic 
sample, was derived from a patient with good histological response in the primary tumor but 
who relapsed nonetheless. L2635 originated from a patient with good histological response to 
pre-operative chemotherapy who is currently in persistent first complete remission (follow-up 
since diagnosis 20 months). Collected tissue pieces were dissociated mechanically and cultured 
in RPMI 1640 medium supplemented with 20% FCS and PS. When subconfluence was reached, 
cells were harvested using 0.05% Trypsin/EDTA (Invitrogen) and passaged. Chromium release 
assays and flow cytometric analyses were performed no later than at passage 3.
Isolation and culture of NK cells
PBMCs were isolated using a Ficoll density gradient separation followed by NK cell enrichment 
using the MACS NK enrichment kit and LS columns (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturer’s protocol. Purity of NK cells was assessed by flow cytometry and was 
typically around 95% (less than 1% T cells). NK cells were cultured in AIM-V medium (Invitrogen), 
supplemented with 10% pooled human AB serum (Sanquin, Rotterdam, Netherlands), PS and 
glutamine (Glutamax I, Invitrogen). Activated NK cells were cultured with 10 ng/mL recombinant 
human interleukin-15 (IL-15) for three days or two weeks (Peprotech, Rocky Hill, NJ).
Flow cytometry
Surface staining of cells for flow cytometry was performed as described elsewhere [20]. 
Intracellular flow cytometry staining was done using permeabilization and fixation kits as per 
manufacturer’s instructions (00-5123; 00-5223; 00-8333, eBioscience, San Diego, CA). An overview 


























and healthy controls was performed on a BD LSRII and analyzed using FACS Diva Software 5.0 
(both from Becton Dickinson, San Diego, CA). Mean fluorescence intensity (MFI) of cell subsets 
was calculated by subtracting the MFI of a negative population from the MFI of the population 
of interest within one individual to correct for interindividual variability of background staining. 
Flow cytometry of cell lines and purified NK cells was performed on a FACScalibur, and analyzed 
using Cellquest software (both Becton Dickinson). MFI ratio was calculated by MFI of the specific 
staining relative to the MFI of the appropriate isotype control staining.
Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue array sections as previously described 
[183]. Testis was used as a positive control for the activating NK ligands and tonsil for the inhibitory 
ligands. Sections were blocked using 10% swine or goat serum in PBS and subsequently incubated 
with primary antibody diluted in 0.5% bovine serum albumin (BSA) in PBS overnight. As a negative 
control 0.5% BSA/PBS without primary antibody was used. All primary antibodies are listed in 
Suppl. Table 5.4. Anti-rabbit/rat/mouse PowerVision Poly-HRP (Leica Biosystems, Newcastle Upon 
Tyne, United Kingdom) was used as a secondary antibody, except for the MICA staining, in which 
case the Universal LSAB+ Kit (DAKO, Glostrup, Denmark) was used. DAB+ (DAKO) was used as a 
chromogen. Sections were counterstained using Mayer’s hematoxylin. Tissue array images were 
acquired using the MIRAX slide scanner (3DHISTECH, Budapest, Hungary) and analyzed using the 
MIRAX viewer version 1.14 (3DHISTECH). Slides were scored by two observers (EPB and PCWH) 
in a modified semi-quantitative scoring system as proposed by Ruiter et al [225]. The intensity of 
staining was scored as 0, 1, 2 or 3 indicating absent, weak, clear or strong expression, respectively. 
Percentages of positive cells were scored as 0 for 0%, 1 for 1-30%, 2 for 31-70% and 3 for 71-100%.
Chromium release assays
Cytotoxicity was determined in standard four hour Chromium release assays. For experiments 
using PBMCs of OS patients and controls, PBMCs were thawed from storage in liquid nitrogen 
and allowed to recover for 16 h in RPMI 1640 supplemented with 10% FCS and PS. The E:T ratios in 
these experiments were corrected for the percentage of NK cells of PBMCs as determined by flow 
cytometry. For all other experiments, purified unstimulated or IL-15 activated NK cells were used 
as effector cells. Target cells (cell lines or primary cultures) were incubated with 100 μCi sodium-
51-chromate (PerkinElmer, Wellesley, MA) for 1 h. Effector cells (PBMCs, unstimulated purified NK 
cells or activated NK cells) were incubated for 4 h with 2500 target cells at eight effector:target 
(E:T) ratios in triplicate. Maximum and spontaneous release was determined by incubating 
targets in 2N HCl or medium, respectively. Supernatants were harvested and measured in a 
gamma-counter (Wallac, PerkinElmer). Specific lysis was determined as: (experimental release-
spontaneous release)/(maximum release-spontaneous release) × 100%. In all NK cytotoxicity 
experiments, K562 and EBV were used as positive and negative controls, respectively. For blocking 
experiments, NK cells preincubated with blocking anti-NKG2D (R&D systems, clone 149810) and/
or blocking anti-DNAM-1 (BD Pharmingen, clone DX11) at a concentration of 20 μg/mL. To disrupt 
















1 μM Concanamycin A (Sigma-Aldrich, Zwijndrecht, the Netherlands) prior to adding the NK cells 
to the target cells. To block Fas-induced apoptosis, target cells were preincubated with 2μg/mL 
neutralizing anti-Fas antibody (Clone ZB4, Millipore, Temecula, CA).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 (LaJolla, CA). Data with non-normal 
distribution or small sample size were analyzed using non-parametric methods (Mann-Whitney U, 
Kruskal-Wallis, Friedman and Dunns tests) and data with normal distribution were analyzed using 
parametric methods (t-tests, one way analysis of variance (ANOVA) and Bonferroni’s tests). Survival 
analyses were performed using Kaplan-Meier curves and compared using the logrank method.
RESULTS
Osteosarcoma cells are highly susceptible to IL-15 activated allogeneic 
NK cells 
We tested eight osteosarcoma cell lines for susceptibility to cytolytic activity of freshly isolated 
(‘unstimulated’) and IL-15 cultured (‘activated’) healthy donor derived NK cells. All cell lines 
were lysed by unstimulated allogeneic NK cells at levels comparable to the positive control cell 
line K562 (Fig. 5.1a and b). Cytolysis of all osteosarcoma cell lines was strongly enhanced when 
IL-15 cultured allogeneic NK cells were used. 
a b
Fig. 5.1 Osteosarcoma cells were sensitive to lysis by freshly isolated NK cells (solid lines) and NK cells cultured 
in IL-15 for 2 weeks (dashed lines). a, examples of percentage of specific lysis are shown for the osteosarcoma 
cell lines SAOS-2 (●), 143B/HOS (○), IOR/OS-14 (■) and ZK-58 (□). Cell lines were incubated with increasing 
numbers of NK cells (E:T; effector to target ratio). Error bars represent standard error of the mean lysis of a 
representative experiment performed in triplicate. b, mean percentage of specific lysis by unstimulated (white 
bars) and IL-15 activated (black bars) NK cells of the osteosarcoma cell lines 143B/HOS, SJSA-1, OHS, U2-OS, 
SAOS-2, IOR/OS-14, HOS and ZK-58 at an effector to target ratio of 10:1. Error bars represent standard error of 
the mean of independent experiments using different healthy donor NK cells. Numbers in the bars represent 
number of experiments. K562 and an EBV transformed B-LCL (“EBV”) were used as positive and negative controls, 
respectively. Mann-Whitney-U test was done comparing IL-15 activated NK cells with unstimulated NK cells for 


























Osteosarcoma cells express inhibitory and activating NK cell ligands
Osteosarcoma cells expressed activating NK cell ligands and HLA class I, both in vivo and in vitro 
(Table 5.1 and Fig. 5.2). All osteosarcoma cell lines expressed HLA class I, at least 3/5 NKG2D ligands 
and both DNAM-1 ligands. Expression of ligands in vivo was determined on the tissue array containing 
144 samples of 88 patients. In chemotherapy-naive tumor material MICA, DNAM-1 ligands and 
HLA class I were also expressed, albeit at different levels (Fig. 5.2a). In tumor cells persisting after 
chemotherapy, levels of MICA, HLA class I and β-2 microglobulin expression were unaltered but 
the expression levels of the DNAM-1 ligands CD112 and CD155 were significantly decreased (Fig. 
5.2b). There was a trend for patients with high (score > 4) vs. low (score </= 4) expression of MICA in 
pre-treatment diagnostic biopsies to have better overall survival (n=53, P-value logrank test = 0.07). 
Expression level of HLA class I in diagnostic biopsies as determined by staining with antibodies 
recognizing β-2 microglobulin, HLA-A and HLA-B/C did not correlate with tumor progression. 
NK cells lyse osteosarcoma cells in a DNAM-1 and NKG2D dependent 
manner
NK cell-mediated cytolysis of osteosarcoma cells was dependent on NKG2D and DNAM-1 pathways, 
as was demonstrated by blocking DNAM-1, NKG2D or both receptors (Fig. 5.3). In resting NK cells 
the DNAM-1 pathway appeared to predominate the cytolytic potential, whereas the contribution 
of the NKG2D pathway was more prominent in the cytolytic activity of IL-15 cultured NK cells. In 
case of IL-15 cultured NK cells, blockade of both pathways was required for optimal inhibition of 
NK cytolytic activity. Levels of expression of HLA class I did not correlate with magnitude of lysis by 
unstimulated or IL-15 activated NK cells. Similarly, levels of expression of ligands for the activating 
receptors NKG2D or DNAM-1 did not correlate with degree of lysis by NK cells (data not shown).
Chemotherapy resistant osteosarcoma cells remain sensitive to lysis 
by IL-15 activated NK cells
To study whether chemotherapy resistant cell lines have become resistant to NK cell mediated 
lysis as well, the sensitivity of a panel of chemotherapy resistant variants of the osteosarcoma 
cell lines SAOS-2 and U2-OS (selected in vitro to be resistant to DX, CDDP or MTX) to lysis by 
NK cells was tested (Fig. 5.4a). Although some SAOS variants, e.g. CDDP, were less sensitive to 
lysis by resting NK cells, activation of NK cells with IL-15 greatly enhanced lysis of all U2-OS and 
SAOS-2 chemotherapy resistant variant cell lines (Fig. 5.4a). Expression levels of NKG2D and 
DNAM-1 ligands were similar in chemotherapy resistant variants and parental cell lines, as was 
the dependency on NKG2D and DNAM-1 signaling in cytotoxicity assays (Table 5.1 and Suppl. 
Fig. 5.1). Expression levels of HLA class I and of the adhesion molecules ICAM-1 and LFA-3 were 
unaltered in the chemotherapy resistant variants, but expression of CD95 (death receptor Fas) 
was lost in the SAOS-2 CDDP and DX-resistant variants (Table 5.1 and Fig. 5.4b). Since the loss 
of CD95 could provide an explanation for reduced susceptibility to NK cell induced lysis, we 
performed blocking experiments in which both CD95 and the granule exocytosis pathway were 
blocked with a blocking antibody and Concanamycin A, respectively. These experiments were 
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Fig. 5.2 a, representative example of immunohistochemical staining of ligands for the activating receptors 
NKG2D (MICA) and DNAM-1 (CD112 and CD155) and of β2-microglobulin, HLA-A (HCA2) and HLA-B/C (HC10) on 
an osteosarcoma sample. b, overview of the results of immunohistochemical stainings on pre-chemotherapy and 
post-chemotherapy samples of the primary tumor as well as metastatic osteosarcoma tissue. Expression levels 
of CD112 and CD155 but not the other ligands decreased significantly upon chemotherapy treatment (P-value 
Kruskal-Wallis test <0.001=***). c, example of flow cytometry plots for MICA, CD112, CD155 and HLA class I for the 


























GrB but not the CD95 cytolytic pathway, almost completely abrogated NK cytolytic potential, 
demonstrating the predominance of the GranzymeB pathway in NK cell mediated lysis of 
parental as well as CDDP resistant variants of osteosarcoma cells (Fig. 5.4c). Similar results were 
obtained when the U2-OS parental cell line was used (data not shown).
Peripheral blood NK cell phenotype is unaltered and cytolytic 
potential is unimpaired in newly diagnosed osteosarcoma patients
Since peripheral NK cells in patients with other tumor types show altered phenotype and function, 
we analyzed PBMCs of 22 newly diagnosed osteosarcoma patients and 23 age-matched healthy 
controls by flow cytometry for NK cell number and phenotype (Suppl. Fig. 5.2a). NK cell number 
and phenotype were comparable between patients and controls (Fig. 5.5a and Suppl. Fig. 5.2b 
and c). Following three days of culture in IL-15, there was a larger increase in NKG2D and granzyme 
B expression levels on both CD56dim and bright NK cells of osteosarcoma patients than of healthy 
controls (Fig. 5.5a and Suppl. Fig. 5.2c). We assessed the functionality of NK cells of osteosarcoma 
patients at diagnosis in cytotoxicity assays using unstimulated and 3 days IL-15 activated PBMCs as 
effector cells. Resting NK cells from osteosarcoma patients and healthy donors lysed the allogeneic 




Fig. 5.3 a, cytolysis of U2-OS by unstimulated (solid lines) and IL-15 activated (dashed lines) NK cells was almost 
completely abrogated when the NK cells were pre-incubated with both anti (α)-DNAM-1 and α-NKG2D blocking 
antibodies (■ vs. □). Unstimulated NK cells were most dependent on DNAM-1 (○) signaling, whereas activated 
NK cells were most dependent on NKG2D (●). Error bars represent standard error of the mean lysis of experiment 
performed in triplicate. Similar results were obtained for SAOS-2, HOS and ZK-58 using unstimulated (b) and IL-15 
activated NK cells (c). Bars represent mean lysis in at least three independent experiments using healthy donor 
NK cells; error bars represent standard error of the mean. Friedman test, Dunns post test compared to non-




















Fig. 5.4 a, lysis of U2-OS variants resistant to doxorubicin (DX), methotrexate (MTX) or cisplatinum (CDDP) 
was comparable to lysis of the parental control. The SAOS-2 CDDP resistant line was less sensitive to lysis by 
unstimulated NK cells than its parental control (Friedman test P-value = 0.001 and Dunns post test compared 
to parental cell line P-value <0.001). NK cell activation (“IL-15 +”) increased lysis in all cases. Error bars represent 
standard error of the mean lysis in at least six independent experiments. b, SAOS-2 expressed the death receptor 
CD95 (Fas; black line) whereas expression was lost in the cisplatinum resistant variant of SAOS-2 (dashed line). 
Isotype matched control staining is shown in grey. c, the granzyme/perforin pathway was the main cytotoxic 
pathway by which NK cells lysed SAOS-2 and its chemotherapy resistant variants, as shown by inhibition of 
granule exocytosis by concanamycin A. Blocking Fas resulted in a further decrease in lysis of SAOS-2, but not of 
the chemotherapy resistant variants. Bars represent mean lysis of experiment performed in triplicate; error bars 












































































































































































































































































































































































































































































































































































































































































































better than healthy donor NK cells (ANOVA, Bonferroni’s post-test P-value <0.0001). Percentage 
specific lysis of HOS correlated with the level of NKG2D expression on CD56 dim NK cells (Fig. 5.5c; 
Pearson correlation efficient r2 0.45, P-value<0.0001) and similar results were obtained for the 
correlation with Granzyme B expression (not shown). To test whether the functional integrity of 
NK cells from osteosarcoma patients was also preserved towards autologous tumor cells, we took 
advantage of the fact that we were able to derive short-term cultured cells from fresh biopsies. 
Autologous, patient derived NK cells lysed short-term cultured tumor cells to a similar degree as 
allogeneic NK cells from healthy controls (Fig. 5.5d). In all cases, culture of both autologous and 
allogeneic NK cells in IL-15 resulted in greatly enhanced tumor cell killing.
DISCUSSION
There is increasing interest in the potential for NK cells to be used in the treatment of pediatric 
solid tumors [41]. Previous studies have shown that osteosarcoma cell lines may be sensitive 
to cytokine activated NK cell mediated cytotoxicity [104;132;143;156-159;165;191]. However, 
little is known about the mechanisms involved or the extent to which short-term cultured 
or chemotherapy resistant osteosarcoma cells are susceptible to NK cell mediated lysis. In 
addition, there is some evidence for NK cell mediated anti-osteosarcoma activity in vivo. Post-
operative osteomyelitis-associated inhibition of tumor growth was dependent on the activation 
of monocytes and NK cells in a murine osteosarcoma model [242]. In human osteosarcoma, 
treatment with interleukin (IL)-2 in a small cohort of patients resulted in NK cell activation 
which was correlated with better clinical outcome [151]. Together, these studies suggest that 
exploitation of NK cell activity may be a suitable therapeutic tool in the adjuvant treatment 
of osteosarcoma. In the present study, we demonstrate that osteosarcoma cells are highly 
susceptible to NK cell mediated cytolysis (Fig. 5.1). Osteosarcoma cells expressed activating 
NKG2D and DNAM-1 ligands in vivo as well as in vitro and lysis was dependent on the interaction 
between these ligands on osteosarcoma cells and their receptors on NK cells (Figs. 5.2 and 5.3). 
Despite expression of the potentially inhibitory KIR ligand HLA class I by osteosarcoma cells, all 
cell lines and short-term cultures were highly sensitive to lysis by IL-15 activated NK cells (Table 
5.1 and Figs. 5.1 and 5.5d). Together, these data suggest that the balance between expression of 
activating and inhibitory ligands in osteosarcoma is shifted towards activation.
To investigate if NK cell based immunotherapy is also feasible for patients with chemotherapy 
resistant disease, we tested the susceptibility of in vitro selected chemotherapy resistant osteosarcoma 
cells to NK cell mediated lysis. Methotrexate (MTX), doxorubicin (DX) or cisplatin (CDDP) resistant 
variants of the cell lines SAOS-2 and U2-OS remained sensitive to lysis by IL-15 activated NK cells (Fig. 
5.4a). NK cells kill their targets by the release of perforin and granzyme containing granules and by 
the ligation of death receptors such as CD95 (Fas) [44;234]. Expression of CD95 was lost in the CDDP 
and DX resistant SAOS-2 variants (Table 5.1 and Fig. 5.4), but dual blocking studies demonstrated only 
a minor role for Fas ligation in the lysis of osteosarcoma by cytokine activated NK cells. Expression 
of Fas is frequently lost in osteosarcoma pulmonary metastases, but our data shows that this will 


























Studies on the feasibility of immunotherapeutic strategies in bone tumors are often 
hampered by the technical difficulty to isolate viable fresh tumor cells for functional testing. To 
circumvent this problem, we used short-term cultured cells. Susceptibility to NK cell mediated 
lysis was determined no later than at passage three. Four out of five cultures originated from 
patients with chemotherapy resistant disease (L2531, L2792, L2599 and L2808). Still, all were 
highly sensitive to lysis by cytokine activated autologous and allogeneic NK cells (Fig. 5.5d). 
Importantly, our experiments on in vitro selected chemotherapy resistant cells and on short-
term cell cultures generated from patients with chemotherapy resistant disease in vivo show that 
IL-15 activated NK cells are capable of lysis of osteosarcoma cells resistant to chemotherapeutic 
agents commonly used in high-grade osteosarcoma treatment.
In many tumor types, including Ewing sarcoma, host immune cells have decreased 
functionality as compared to healthy donor cells [80;128;272]. In these cases, using allogeneic 
immune cells instead of autologous cells is an attractive option to increase efficacy. However, 
it also increases the risk of serious complications such as graft-versus-host-disease. Our data 
shows that NK cells of osteosarcoma patients are as potent as NK cells of healthy controls in 
lysing osteosarcoma cells. Remarkably, upon activation with IL-15, patient derived NK cells even 
showed a larger increase in expression of NKG2D and GranzymeB than healthy donor derived 
NK cells, which correlated with an increased lysis of the osteosarcoma cell line HOS (Fig. 5.5a 
and Suppl. Fig. 5.2c). This, and the lysis of autologous tumor cells by ex vivo IL-15 activated NK 
cells, indicates that immunotherapeutic strategies employing activated autologous NK cells 
could be as successful as allogeneic NK cells in the treatment of osteosarcoma. In preclinical 
validation studies we obtained evidence that IL15 and IL2 stimulated NK cells have similar 
cytolytic activity against various tumor cell lines [268]
In conclusion, chemotherapy resistant and sensitive osteosarcoma cells were lysed at high 
levels by NK cells, particularly when NK cells were cytokine activated. Lysis of osteosarcoma 
cells was dependent on DNAM-1 and NKG2D, ligands of which were expressed by osteosarcoma 
cells both in vivo and in vitro. In contrast to what has been reported in patients with other tumor 
types, there was no intrinsic functional NK cell defect which could hamper anti-tumor activity. 
Our study shows a potential benefit of either activating NK cells in vivo by the administration 
of cytokines or adoptive transfer of ex vivo activated autologous or allogeneic NK cells in the 
treatment of high-grade osteosarcoma.
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Suppl. Fig. 5.1 The relative contribution of NKG2D and DNAM-1 ligands to the lysis of SAOS-2 and its chemotherapy 
resistant variants was similar, as demonstrated by blocking DNAM-1, NKG2D or both receptors on unstimulated 
(a) and IL-15 activated (b) NK cells. Similar results were obtained in U2-OS (c and d). Error bars represent standard 
error of the mean lysis in at least three independent experiments using healthy donor NK cells. DX; doxorubicin 













































Suppl. Fig. 5.2 a, representative example of flow cytometry results of unstimulated peripheral NK cell 
compartment. The CD3 CD56 plot was gated on lymphocytes based on forward and sideward scatter. Monocytes 
were gated out by excluding CD14 stained cells (not shown). NK cells were defined as CD3-CD56+ cells and were 
divided in a CD56 bright and a CD56 dim subset. Expression of NKG2D, DNAM-1, CD16, perforin and granzyme B 
was determined for CD56 bright (black histogram and dots) and CD56 dim (grey histogram and dots) subsets. 
b, patients and controls had similar numbers of NK cells. c, following culture for 3 days in IL15, there was a larger 
increase in expression level of Granzyme B in NK cells of patients than of healthy controls. Patients and controls 
had similar levels of CD16, DNAM-1 and perforin on NK cells. In both patients and healthy controls, levels of 
CD16 decreased in CD56dim and bright NK cells and levels of perforin increased in CD56bright and decreased in 
CD56dim NK cells upon IL-15 treatment. ANOVA, P-value <0.0001. Bonferroni’s multiple comparison post-test; 
















Suppl. Table 5.1 Composition of osteosarcoma tissue array
Number of samples
(of nr of patients) Type of sample
73 (73) Pre-treatment samples of the primary tumor
45 (45) Post-treatment samples of the primary tumor
20 (13) Lung metastases
3 (3) Other metastases (2 bone and one lymph node metastasis)
3 (3) Local relapses


























Suppl. Table 5.2 Clinicopathological details of patients in this study
Tissue array
Peripheral blood NK cell analysis
Osteosarcoma patients Healthy donors
Total nr of patients 88 22 23
Age in years: median (range) 15.4 (4-44) 16 (9-56) 20 (8-55)
Sex n (%) n (%) n (%)
Male 47 (53.4%) 10 (45.5%) 11 (47.8%)
Female 41 (46.6%) 12 (54.5%) 12 (52.2%)
Location of primary tumor
Distal femur 40 (45.5%) 11 (50%)
Proximal tibia/fibula 27 (30.7%) 4 (18.2%)
Proximal humerus 10 (11.4%) 4 (18.2%)
Other long bones 9 (10.2%) 3 (13.6%)
Axial skeleton 1 (1.1%) 0
Hand 1 (1.1%) 0
Histological subtype





Telangiectatic 6 (6.8%) 4 (18.2%)
High-grade surface osteosarcoma 1 (1.1%) 0
Small cell osteosarcoma 2 (2.3%) 0
Date of diagnosis: Jan 1981- Sep 2003 Feb 2007 - Apr 2008
Treated according to protocols: EORTC 80831,  
80861 and 80931
Euramos-1
Suppl. Table 5.3 Clinicopathological details of primary cultures
Primary 
culture
Origin of primary 
culture Sex Age (y)




L2531 Local relapse Male 17 Osteoblastic Distal femur
L2808 Lung metastasis Male 18 Osteoblastic Distal femur
L2792 Local relapse Female 31 Fibroblastic Proximal humerus
L2599 Diagnostic biopsy Male 13 Osteoblastic Distal femur
















Suppl. Table 5.4 Antibodies used for immunohistochemistry (IHC) and flow cytometry (FC)
Antibody Catalog/ clone nr Company Application
b2-microglobulin A0072 DAKO (Glostrup, Denmark) IHC, antigen retrieval (AR): 
Citrate, 0.01 M, pH 6
HLA-A HCA-2 Kindly provided by J.Neefjes (NKI, 
Amsterdam, the Netherlands)
IHC, AR: Citrate, 0.01 M, pH 6
HLA B/C HC10 Kindly provided by J.Neefjes IHC, AR: Citrate, 0.01 M, pH 6
MICA AF1300 R&D systems (Minneapolis, MN) IHC, AR: Citrate, 0.01 M, pH 6
CD155 HPA012568 Sigma Aldrich (Zwijdrecht, the 
Netherlands)
IHC, AR: EDTA, 1 mM, pH 8
ULBP-1 HPA007547 Sigma Aldrich IHC, AR: Citrate, 0.01 M, pH 6
CD112 HPA012759 Sigma Aldrich IHC, AR: EDTA, 1 mM, pH 8
MICA MAB1300 R&D systems FC, cell lines
MICB FAB1599A R&D systems FC, cell lines
ULBP-1 IC1380P R&D systems FC, cell lines
ULBP-2 FAB1298A R&D systems FC, cell lines
ULBP-3 MAB1517 R&D systems FC, cell lines
CD48-PE IM1837U Beckman Coulter Immunotech 
(Marseille, France)
FC, cell lines
CD155 IM2755 Beckman Coulter Immunotech FC, cell lines
CD112-PE IM3452 Beckman Coulter Immunotech FC, cell lines
HLA-A/B/C-FITC 555552 BD Pharmingen (San Diego, CA) FC, cell lines
CD54-PE 555511 BD Pharmingen FC, cell lines
CD58-PE 555921 BD Pharmingen FC, cell lines
CD95-PE 340480 BD Pharmingen FC, cell lines
goat anti-mouse APC 550826 BD Pharmingen FC, secondary antibody
mIgG1-FITC 639 Beckman Coulter Immunotech FC, isotype control
mIgG2b X0944 DAKO FC, isotype control
mIgG2a MAB0031 R&D FC, isotype control
mIgG1-PE 349053 BD Pharmingen FC, isotype control
mIgG1 MAB002 R&D FC, isotype control
mIgG2a-PE 349053 BD Pharmingen FC, isotype control
CD3-PerCPCy5.5 332771 BD Pharmingen FC, purity of isolated NKs
CD20-FITC 345792 BD Pharmingen FC, purity of isolated NKs
CD14-APC 340436 BD Pharmingen FC, purity of isolated NKs
CD56-PE R7251 DAKO FC, purity of isolated NKs
CD3-Pacific Blue 558117 BD Pharmingen FC, PBMCs
CD14-PerCPCy5.5 550787 BD Pharmingen FC, PBMCs
DNAM-PE 559789 BD Pharmingen FC, PBMCs
GranzymeB-Alexa700 557971 BD Pharmingen FC, PBMCs
NKG2D-APC 558071 BD Pharmingen FC, PBMCs
CD56-PECy7 A21692 Beckman Coulter Immunotech FC, PBMCs
CD16-FITC IM0814 Beckman Coulter Immunotech FC, PBMCs
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ABSTRACT
High-grade osteosarcoma has a poor prognosis with an overall survival rate of about 60 percent. 
The recently closed European and American Osteosarcoma Study Group (EURAMOS)-1 trial 
investigates the efficacy of adjuvant chemotherapy with or without interferon-α. It is however 
unknown whether the interferon-signaling pathways in immune cells of osteosarcoma patients 
are functional. We studied the molecular and functional effects of interferon treatment on 
peripheral blood lymphocytes and monocytes of osteosarcoma patients, both in vivo and ex 
vivo. In contrast to other tumor types, in osteosarcoma, interferon signaling as determined 
by the phosphorylation of signal transducer and activator of transcription (STAT)1 at residue 
701 was intact in immune cell subsets of 33 osteosarcoma patients as compared to 19 healthy 
controls. Also, cytolytic activity of interferon-α stimulated natural killer cells against allogeneic 
(n = 7 patients) and autologous target cells (n = 3 patients) was not impaired. Longitudinal 
monitoring of three osteosarcoma patients on interferon-α monotherapy revealed a relative 
increase in the CD16-positive subpopulation of monocytes during treatment. Since interferon 
signaling is intact in immune cells of osteosarcoma patients, there is a potential for indirect 
immunological effects of interferon-α treatment in osteosarcoma.
INTRODUCTION
High-grade osteosarcoma is a primary malignant bone tumor with an overall survival rate of about 
sixty percent [8]. Intensification of chemotherapeutic treatment has not led to improved outcome, 
and other therapeutic modalities are currently under investigation [141]. The recently closed 
for accrual European and American Osteosarcoma Study Group (EURAMOS)-1 trial investigates 
whether maintenance treatment with interferon(IFN)-α-2b after standard chemotherapy for 
osteosarcoma patients who have a good response to preoperative chemotherapy (i.e., >90% 
necrotic tumor tissue) is effective [160;278]. IFN-α has proven anti-tumor effect in several tumor 
types, such as hairy cell leukemia and renal cell cancer, and has been used in osteosarcoma 
patients as adjuvant treatment in Scandinavia since the 1970s [163;168;249].
The anti-proliferative effect of IFN-α on osteosarcoma cells has been shown in vitro and in a 
xenograft model in nude mice [31;154]. Also, expression of IFN receptors on human osteosarcoma 
cells is associated with a better prognosis [133]. However, IFN-α can also exert indirect anti-
tumor activity; for example, through immunostimulatory effects. The type I IFNs (IFN-α and -β) 
binds to the IFN type I receptor consisting of the two subunits IFNAR1 and IFNAR2, which is 
expressed by immune cells such as natural killer (NK) cells and monocytes [100;207]. Indirect 
anti-tumor effects of type I IFNs were essential for the clearance of immunogenic sarcomas in 
IFNAR1 deficient mice, since it was dependent on the expression of IFNAR1 on hematopoietic 
host cells and not on tumor cells [61]. Whether similar indirect anti-tumor effects also occur in 
the treatment for human osteosarcoma with type I IFNs is unknown. The binding of type I and 
type II (IFN-γ) IFNs to their respective receptors results in the activation of Janus Kinase (JAK), 
subsequent phosphorylation of signal transducer and activator of transcription (STAT) and finally 
transcription of target genes. Phosphorylation of STAT1 at tyrosine residue 701 occurs rapidly 
following receptor–ligand interaction and is critical for both type I and type II IFN signaling [54]. 
IFN signaling as determined by STAT1 phosphorylation was impaired in lymphocytes of patients 
suffering from breast cancer, melanoma, and gastrointestinal cancer [27;51;52;62]. Impaired IFN 
signaling may be rescued at the level of JAK-1 induced STAT1 phosphorylation; for example, by 
interleukin (IL)-12 pre-treatment, as was shown in a murine melanoma model [139].
Here, we addressed the molecular and functional effects of IFN treatment on immune cell 
subsets of osteosarcoma patients, both in vivo and ex vivo. To interpret the future results of 
the IFN-α treatment arm of the EURAMOS-1 trial, it is essential to know whether IFN-signaling 
pathways in immune cells of osteosarcoma patients are intact.
PATIENTS AND METHODS
Patients
Peripheral blood mononuclear cells (PBMCs) of 33 newly diagnosed osteosarcoma patients and 
19 healthy controls were available for flow cytometric evaluation of IFN-induced phosphorylation 
of STAT1 (Table 6.1). PBMCs of 7 patients and 7 controls were available for cytolytic experiments. 
From three osteosarcoma patients treated with IFN-α monotherapy following the completion of 































prior to the start of IFN-α monotherapy and at one or two time points during the first few weeks 
of treatment with IFN-α (subcutaneous PegIntron, 0.5 μg/kg/week for 4 weeks, then dose 
escalation to 1.0 μg/kg/week). PBMCs were obtained after written informed consent, approved 
by the Institutional Review Board. All samples were handled in a coded fashion.
Culture of cell lines and PBMCs
The cell line K562 (obtained from ATCC) and PBMCs were cultured in RPMI 1640 medium 
(Invitrogen, Carlsbad, CA) with 10% fetal calf serum (FCS, Invitrogen) and 1% penicillin/
streptomycin (P/S, Invitrogen). PBMCs were isolated by Ficoll density gradient centrifugation 
and stored in liquid nitrogen. After thawing, cells were allowed to recover overnight, except 
when used for flow cytometric evaluation of dendritic cell (DC) activation, in which case, cells 
were analyzed immediately. For cytolytic assays, cells were cultured overnight with or without 
100 IU/mL IFN-α (Roche, Basel, Switzerland). Prior dose-finding pilot experiments determined 
this dose to result in good cell viability and reproducible NK cell activation (data not shown). 
The primary cell culture L2635 was established from a pre-treatment biopsy of osteosarcoma 
patient 398 as described previously and maintained in RPMI 1640 with 20% FCS and 1% P/S [34].
Flow cytometric evaluation of IFN-induced phosphorylation of STAT1
Cells were stained with surface staining antibodies in staining buffer (PBS with 0.05% bovine 
serum albumin without sodium azide) for 30 min at 37°C. Surface staining antibodies used 
for natural killer (NK) and T-cell subsets were fluorescein isothiocyanate (FITC)-conjugated 
anti-CD3 (349201, BD, San Diego, CA) and allophycocyanin (APC)-conjugated anti-CD56 (2474, 
Table 6.1 Clinicopathological details of osteosarcoma patients and healthy controls included.
osteosarcoma healthy controls
n 33 19
Male 18 (54,5 %) 12 (63.2 %)
age median (range) 16 (6-56) 17 (8-45)
location primary tumor
distal femur 19 (57.6 %)
prox tibia 6 (18.2 %)
prox humerus 5 (15.2 %)
other long bone 3 (9.1 %)
histological subtype




telangiectatic 4 (12.1 %)
















IOtest/Immunotech, Marseille, France). Antibodies used for monocyte and B cell subsets 
were FITC-conjugated anti-CD20 and APC-conjugated anti-CD14 (345792 and 340436, BD). 
Cells were stimulated with or without 1,000 IU/mL IFN-α or IFN-γ for 15 min at 37°C and fixed 
in 4% paraformaldehyde, as previously described by Critchley-Thorne et al. [15]. Cells were 
permeabilized using ice-cold Perm Buffer III (BD Phosflow) for 30 min and stained for 60 min on 
ice with phycoerythrin (PE)-conjugated anti-STAT1 (directed against the N-terminus of STAT1 
to determine total STAT1 levels, 558537, BD) and peridinin chlorophyll protein (PerCP)-Cy5.5-
conjugated anti-pY701-STAT1 (directed against phosphorylated tyrosine residue 701 of STAT1 
to determine the levels of phosphorylated STAT1, 560113, BD). Isotype control antibodies were 
used to correct for the background levels of fluorescence. All flow cytometric analyses were 
done on a FACScalibur with Cellquest software (both BD).
Flow cytometric evaluation of PBMC subsets
PBMC subsets were determined as follows: T cells were CD3-PerCP-Cy5.5-positive (332771, 
BD), NK cells were CD3-PerCP-Cy5.5-negative, and CD56-PE-positive (R7251, Dako, Glostrup, 
Denmark), B-cells were CD20-FITC-positive (345792, BD), and monocytes were CD14-APC-
positive (340436, BD). Myeloid dendritic cells (mDCs) were CD3-, CD19-, and CD14-negative 
(all PerCP-Cy5.5-conjugated, 332771, 332780, and 550787, BD) and BDCA-1- and BDCA-2-positive 
(PE-conjugated, Miltenyi Biotec, Bergisch Gladbach, Germany). Activation status of mDCs 
was determined by evaluating mean fluorescence intensities of HLA-DR-APC (347403, BD) 
and CD86-FITC (555657, BD). Plasmacytoid dendritic cells (pDCs) were CD3-, CD19-, and CD14-
negative and BDCA-2-APC-positive (Miltenyi). Activation status of pDCs was determined with 
anti-CD86-FITC and anti-HLA-DR-PE (555657 and 347367, BD). Monocytes were evaluated by 
CD14-PerCP-Cy5.5, CD16-PE (347617, BD), HLA-DR-APC, and CD86-FITC.
Cytolytic assays
Four hour chromium release cytolytic assays were performed as described earlier [34]. Briefly, 
target cells were incubated with 3.7 MBq sodium-51-chromate (PerkinElmer, Wellesley, MA) for 1 
h. Effector cells (with or without overnight IFN-α stimulation) were incubated for 4 h with 2,500 
target cells at eight effector:target (E:T) ratios in triplicate. Using these conditions, cytolysis 
observed is caused by NK cells, since antigen-specific T cells (which are present at low frequencies 
if at all) are insufficiently expanded. Therefore, the E:T ratios were corrected for the percentage 
of NK cells of PBMCs as determined by flow cytometry. Maximum and spontaneous release 
was determined by incubating targets in 2N HCl or medium, respectively. Supernatants were 
harvested and counted in a gamma counter (Wallac, PerkinElmer). Specific lysis was determined 
as: (experimental release-spontaneous release)/(maximum release-spontaneous release) × 100%.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 (LaJolla, CA). Two-sided P values 
































Peripheral blood monocytes and lymphocytes of osteosarcoma 
patients have intact interferon-signaling ex vivo
Total STAT-1 levels were similar in peripheral blood subsets of osteosarcoma patients and healthy 
controls. To determine whether the IFN-signaling pathway was intact, we assessed STAT1 
phosphorylation in IFN-stimulated immune cells of controls and patients. Basal levels of phospho-
STAT1 were slightly lower in NK cells of osteosarcoma patients at diagnosis (n = 33) than in NK 
cells of healthy controls (n = 19; Fig. 6.1a), similar to what has been described for melanoma [140]. 
However, in contrast to what has been reported for melanoma, breast cancer, and gastrointestinal 
cancer, IFN signaling was intact in immune cells of osteosarcoma patients, as determined by 
a 15 min ex vivo stimulus with 1,000 IU/mL IFN-α or IFN-γ (results for IFN-α shown in Fig. 6.1, 
results for IFN-γ not shown). Responses were similar in almost all PBMC subsets for patients and 
controls, except for a hyperphosphorylation of STAT1 in B- and NK cells of osteosarcoma patients 
in response to IFN-α (Fig. 6.1b). The functional response of NK cells of osteosarcoma patients 
and healthy controls to IFN-α was similar, as both responded to overnight IFN-α culture with 
increased cytolytic capacity toward the NK cell target K562 (Fig. 6.1c). There was possibly some, 
but not statistically significant trend for correlation between phosphorylated STAT1 in NK cells 
and percentage of specific lysis of K562 (Fig. 6.1d, P value 0.06, Spearman r 0.52).
We previously showed higher cytolytic capacity of IL-15-activated NK cells of osteosarcoma 
patients than of healthy donors [34]. The binding of IL-15 and IFN-α to their respective receptors 
has the association of JAK1 with the receptors in common. Together with Tyk2, this results in 
phosphorylation of STAT1 in case of IFN-α-signaling and together with JAK3 in phosphorylation of 
STAT3 and STAT5 in case of IL-15 signaling. The hyperphosphorylation of STAT1 in response to IFN-α 
and the earlier reported increased cytolytic capacity in response to IL-15 in NK cells of osteosarcoma 
patients as compared to healthy donors could be due to increased functionality of the common 
upstream signaling molecule JAK1. Pro-inflammatory cytokines such as IL-12 potentiate JAK1 
induced STAT phosphorylation [139]. However, levels of IL-12(p70) were similar in plasma of patients 
and controls, and IL-12(p70) levels did not correlate with IFN-α induced STAT1 phosphorylation 
(data not shown). Whether increased STAT1 phosphorylation in NK cells of osteosarcoma patients is 
related to differential expression or activity of JAK1 remains to be investigated.
Phenotypic and functional analysis of PBMCs of osteosarcoma 
patients on IFN-α  monotherapy
In three osteosarcoma patients who received IFN-α monotherapy following chemotherapeutic 
treatment according to the EURAMOS-1 protocol, detailed flow cytometric phenotypic analysis 
of PBMCs was performed during the first few weeks of IFN-α monotherapy. In all three patients, 
B cell numbers were very low (on average 3% of lymphocytes) at the end of chemotherapeutic 
treatment and during IFN treatment returned to levels similar to those at diagnosis, before 
start of chemotherapy (on average about 30% of lymphocytes or 500 cells/μL). No consistent 
















activation status of monocytes, mDCs, or pDCs did not change during the first weeks of 
treatment, as measured by the expression of CD86 and HLA class II.
In all three patients, a reduction in percentage of monocytes was seen during the first 2–8 
weeks of IFN treatment. However, the relative contribution of CD16+ monocyte subpopulation 
increased (Figs. 6.2a, b). CD16+ monocytes are considered “pro-inflammatory” because of the 
high expression of tumor necrosis factor (TNF)-α and low expression of IL-10 [287]. These pro-
inflammatory monocytes may have anti-tumor effects, akin to what has been described for 
“pro-inflammatory” M1 type macrophages. We have recently demonstrated the prognostic 
significance of infiltrating macrophages in osteosarcoma [33]. Further studies are needed 
  
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Fig. 6.1 PBMCs of osteosarcoma patients are normally responsive to IFN-α. a, flow cytometric evaluation of basal 
levels of phosphorylated STAT1 in immune cell subsets shows slightly lower levels of phosphorylated STAT1 in 
NK cells of osteosarcoma patients at diagnosis (n = 33) as compared to healthy donors (n = 19). b, following an 
in vitro stimulus with 1,000 IU/mL IFN-α, hyperphosphorylation of B and NK cells of osteosarcoma patients was 
observed. For both a and b, error bars denote standard error of the mean; student’s t-test P value <0.05 noted 
as *; <0.01 = **. c, lysis of the allogeneic NK cell target K562 by PBMCs of healthy donors (HD) and osteosarcoma 
patients (OS) increased significantly following overnight culture in 100 IU/mL IFN-α (IFN-α +). Effector to target 
(E:T) ratio was corrected for percentage of NK cells. Lysis was similar by healthy donor and osteosarcoma patient 
derived cells. Wilcoxon signed ranked test; P value <0.05 noted as *. d, following overnight culture of PBMCs in 































to determine whether IFN-induced phenotypic changes in peripheral blood monocytes are 
associated with changes in intratumoral macrophage number or phenotype, and whether this 
is associated with altered expression of specific cytokines. However, this will require IFNs to be 
administered earlier, before resection of the primary tumor or relapses.
During in vivo treatment with IFN-α, total STAT1 levels in monocytes, NK cells, and T cells 
increased, but the basal levels of phosphorylated STAT1 did not change in any of the leukocyte 
subsets (data not shown). NK- and T cells, which had been exposed to IFN-α in vivo, showed less 
induction of phosphorylation of STAT1 in response to ex vivo IFN-α stimulation (NK cells shown 
in Fig. 6.2c). Nevertheless, induction of cytolytic capacity against the NK cell target K562 and the 
osteosarcoma culture L2635 following overnight IFN-α stimulation of PBMCs was unimpaired, 
both against autologous and allogeneic targets (example shown for PBMCs of patient 398 and 
its autologous target cells L2635 in Fig. 6.2d), indicating that in vivo treatment with IFN-α has not 
rendered these cells functionally unresponsive to an additional ex vivo IFN stimulus.
The lack of induction of phosphorylated STAT1 during in vivo IFN-α treatment was 
surprising. There are several possible explanations. Phosphorylation of STAT1 is an event that 
occurs rapidly following IFN stimulus. Perhaps, STAT1 phosphorylation in vivo can be observed 
when PBMCs are analyzed within a few hours of first administration of IFN. Further studies are 
needed if this is indeed the case and if so, if this supposed the early activation of the JAK/
STAT pathway in immune cells results in sustained activation of target genes and functional 
pathways. An alternative explanation might be that the level of IFN-induced activation of 
immune cells in vivo is dose-dependent and limited by toxic and adverse effects in vivo [7]. An 
additional in vitro stimulus was able to induce STAT1 phosphorylation and resulted in increased 
cytolytic NK cell activity, suggesting that in vivo IFN-α-induced immune cell activation might 
have been incomplete. On the other hand, it is still possible that the prolonged, relatively low 
level of IFN-α exposure in vivo on PBMCs does result in sustained anti-tumor immune effects; 
for example, through the observed changes in monocytes.
CONCLUDING REMARKS
Treatment for osteosarcoma patients with the anti-proliferative and immunomodulatory 
agent IFN-α could have direct anti-tumor and/or indirect immune-mediated effects. Here, 
we show IFN signaling to be intact in PBMCs of osteosarcoma patients, as determined by the 
phosphorylation of STAT1 and increased NK cell-mediated cytolysis in response to ex vivo IFN. 
Some of the experiments were performed on small sample numbers, but since the results were 
consistent throughout, we believe the results to be valid in determining responsiveness of 
immune cells of osteosarcoma patients to IFN-α. Although the efficacy of IFN-α treatment 
in osteosarcoma will be assessed in the EURAMOS-1 trial, our data indicate that in contrast 
to some other tumor types, immune cells of osteosarcoma patients have retained IFN-
responsiveness. Further clinical studies are needed to establish the extent and efficacy of 
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Discussion and future prospects
Part of this chapter has been adapted from:
Immunotherapy: Is it different for sarcomas? 
Anne-Marie Cleton-Jansen, Emilie P. Buddingh, Arjan C. Lankester
Oncoimmunology. 2012 Mar 1;1(2):255-257
High-grade osteosarcoma is a malignant bone tumor with the highest incidence in young patients. 
The prognosis for patients with metastasized disease remains dismal, despite aggressive surgery 
and intensive chemotherapeutic regimens. In chapters 2 and 3 of this thesis, studies aimed at 
a better understanding of the etiology and prognostic factors of high-grade osteosarcoma 
are described. In chapters 4, 5 and 6 interactions between high-grade osteosarcoma cells 
and innate immune cells are studied. Together, these studies can guide the design of clinical 
studies implementing novel immunotherapeutic regimens. Adding immunotherapy to standard 
treatment regimens will hopefully result in better survival for osteosarcoma patients.
ETIOLOGY AND PROGNOSTIC FACTORS  
OF HIGH-GRADE OSTEOSARCOMA 
The cell of origin of high-grade osteosarcoma remains elusive, but the strong temporal and spatial 
relationship with proliferating and differentiating mesenchymal stromal cells (MSCs), suggests 
that MSCs or early osteoblast precursor cells are likely suspects. Additionally, long term in vitro 
expansion of murine mesenchymal stem cells results in spontaneous oncogenic transformation 
of the cultured cells which form osteosarcoma-like tumors in vivo [113;116;179;183;259]. These 
transformed cells have a near-tetraploid aneuploid karyotype and show loss of the CDKN2 locus, 
similar to human spontaneous osteosarcoma [183]. MSCs derived from cynomolgus macaques 
also transform upon long term in vitro culture [107]. Previously, some groups have reported 
spontaneous transformation of human MSCs, only to later retract these publications because of 
contamination of the cultures with other cell lines [56;218;221-223;260]. In childhood leukemias, 
preleukemic alterations have been found in hematopoietic stem cells years before the leukemia 
developed [164]. The acquisition of additional mutations and subsequent clonal evolution results in 
the outgrowth of a true leukemic clone [110]. Similarly, in solid tumors, the ‘multiple hit’ hypothesis 
postulates that several chronological mutational and cell cycle deregulatory events are necessary 
for cancer to develop [66]. Alternatively, a single catastrophic event, termed chromothripsis, can 
result in highly complex chromosomal rearrangements and oncogenic transformation [102;247]. 
This probably has to occur in a susceptible background, either acquired in specific individual cells 
or as a somatic genetic predisposition. In chapter 2, we hypothesized that MSCs of osteosarcoma 
patients might harbor one or a few of such ‘pre-cancerous’ alterations. The added cellular stress 
of prolonged in vitro culture could then result in additional (pre-) oncogenic hits and a higher 
propensity to spontaneous transformation in osteosarcoma patient derived MSCs than in MSCs 
harvested from healthy donors. Since MSCs originating from the tumor site but predating tumor 
formation were obviously not available, we chose to study MSCs harvested from the iliac crest at 
diagnosis, prior to chemotherapeutic treatment.
On a transcriptional level, downregulation of hematopoietic cell specific Lyn substrate 1 
(HCLS1) was noted in osteosarcoma patient derived MSCs as compared to healthy donor 
derived MSCs, the product of which is involved in B-cell receptor signaling and myelopoiesis 
[75;233]. If downregulation of HCLS1 in osteosarcoma patient derived MSCs has a functional 
role in osteosarcomagenesis is as yet unknown. Despite almost two years in culture, none of 
the samples underwent spontaneous transformation. An increase in binucleation was noted 
upon increasing passage in both osteosarcoma patient and healthy donor derived MSCs. 
Perhaps the binucleation is a result of telomere shortening, anaphase bridges and failed 
cytokinesis [77;123;201]. In any case, functional cell cycle checkpoints were apparently intact in 
both patients and healthy donors, as no transformation occurred and cytogenetic analysis on 
metaphases did not reveal any karyotypic abnormalities.
As was discussed in chapter 2, there are several possible explanations for the observed 
similarities between MSCs derived from osteosarcoma patients and healthy donors. It is possible 

























the precursor cells, but (pre-)oncogenic alterations are not present in MSCs harvested from 
the iliac crest. This does not preclude the presence of preoncongenic alterations in MSCs at 
other sites. For example, there could be somatic mosaicism, similar to what has been shown 
for the enchondromatosis syndromes Ollier disease and Maffucci syndrome [202]. Another 
possibility is that prolonged in vitro culture is insufficient for oncogenic transformation to 
occur. According to the ‘multiple hit hypothesis’, several oncogenic alterations are necessary 
for transformation to occur. Perhaps growth factor signaling (endocrine and paracrine stimuli 
in the microenvironment where osteosarcoma arises, i.e. near the growth plate) or additional 
oncogenic ‘hits’ such as loss of cell cycle control are a prerequisite for oncogenic transformation 
of susceptible MSCs. For example, prolonged culture of MSCs on a background of downregulated 
CDKN2/p16 may yield transformed cells. P53 is essential for preventing cell cycle progression 
in case of failed cytokinesis. Loss of p53 might result in cell cycle progression in case of failed 
cytokinesis with tetraploidy and aneuploidy as a result [77]. A better understanding of what 
drives oncogenic transformation in human MSCs will help elucidate the mechanisms important 
in osteosarcomagenesis, which in turn has the potential to identify targets for therapy.
Pulmonary metastatic disease is the main cause of death for osteosarcoma patients [24]. 
About one in five osteosarcoma patients present with clinically evident pulmonary metastatic 
disease at diagnosis and two in five develop pulmonary metastatic disease during treatment 
or follow up of their disease. Risk factors associated with the development of pulmonary 
metastases include a poor histological response to pre-operative chemotherapy and the 
presence of a primary tumor not amenable to local resection. Despite aggressive multimodal 
therapy, about four in five patients with pulmonary metastatic disease succumb to their disease. 
It is these patients that would benefit most from novel adjuvant (immuno-)therapies. 
In chapter 3, prognostic factors related to the survival of patients with pulmonary metastasized 
high-grade osteosarcoma were studied. Higher metastatic tumor burden (i.e. larger number of 
pulmonary nodules), presence of vital metastases upon resection and male sex were associated with 
an increased risk of death. In chapter 4, genome-wide expression studies were performed to identify 
genes associated with a risk for pulmonary metastatic disease. High expression of macrophage-
associated genes was associated with a lower risk of metastatic disease (discussed in paragraph 7.2.1). 
Together, the results of chapters 3  and 4 show that osteosarcoma patients with morphologically vital 
metastases and a high metastatic tumor burden may benefit from immunotherapeutic strategies 
exploiting migration and activation of monocytes/macrophages towards the tumor site.
INTERACTIONS BETWEEN HIGH-GRADE 
OSTEOSARCOMA CELLS AND INNATE  
IMMUNE CELLS
Tumor-associated macrophages in high-grade osteosarcoma
The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating 
















epithelial cancers, in chapter 4 we show that osteosarcoma metastasis seems to be inhibited by 
the presence of macrophages in the tumor microenvironment.
It is not a coincidence that the ‘Father of Immunotherapy,’ William B. Coley, was a bone sarcoma 
surgeon. The first successful example of immunotherapy was in 1891 when Coley’s toxins, a mixture 
of toxins of streptococcal bacteria was injected into an unresectable sarcoma. The resulting 
immunological reaction led to tumor regression, similar to what has been observed in osteosarcoma 
patients suffering from post-operative infection following resection of their primary tumor [49]. The 
few known permanent responses to Coley’s toxins in carcinoma were in those cases of mesodermal 
origin [246]. Are sarcomas and other tumors of mesodermal origin more immunogenic than 
carcinomas? Or do immune cells have an effect that is different between sarcomas and carcinomas?
The tumor promoting effect of macrophages in carcinomas is well established. Epithelial 
tumors with high numbers of infiltrating immune cells have a poor prognosis as compared with 
cases with few infiltrating cells. This is attributed to a number of properties of the immune 
cells, especially macrophages, which have been shown to be involved with tumor initiation, 
invasion, migration, intravasation and angiogenesis [210]. Especially the stimulating effect on 
tumor invasion and migration of in origin non-motile epithelial cells that are the progenitors 
of carcinomas can be well comprehended. However, it is different for mesenchymal cells, 
which are much less dependent on contact with adjacent cells and thus more motile. These 
cells probably do not need the guidance that immune cells seem to give to carcinoma cells 
in the circulation. Instead, mesenchymal tumor cells might be inhibited in their motility by 
macrophages, which then act as impediment, instead of promoter for invasion. This is of course 
speculative, but it has been reported that macrophage inhibitory factor, MIF, which is produced 
by macrophages, inhibits migration of mesenchymal stem cells [69].
In chapter 4, an expression profiling study in a relatively large series of high-grade 
osteosarcomas was performed, with results corroborating a metastasis inhibiting role for 
macrophages. The ‘expression profile’ associated with non-metastatic behavior of osteosarcoma 
surprisingly consisted of a large number of genes associated with macrophage function, such 
as antigen processing and presentation or pattern recognition, as well as specific monocyte 
and macrophage markers such as CD14 and MSR1. Also a large number of genes with other 
immunological functions, such as cytokine production and phagocytosis were found to be 
upregulated. Expression of the macrophage-associated genes was confined to primary tumor 
tissue and not detected in a panel of 19 osteosarcoma cell line RNA samples, indicating that 
infiltrating immune cells were responsible for this expression profile. Furthermore the results 
were confirmed at the protein level by immuno histochemical staining on a larger patient cohort.
A role for macrophages to prevent or reduce metastases of osteosarcoma is corroborated 
by one of the few efficacious new therapeutic agents that were tested since the successful 
introduction of conventional chemotherapy for osteosarcoma, i.e., liposomal muramyl tri-
peptide (MTP), also known as Mepact® or mifamurtide. This proprietary drug elicits activation 
of macrophages. Although the clinical trial that included adjuvant treatment with mifamurtide 
was initially denounced because of a presumed interaction with one of the chemotherapeutic 

























with non-metastatic osteosarcoma, which was the best achievement in improving outcome in 
decades [169;170]. Our finding that macrophages are associated with less metastases now provides 
a valid biological rationale for the efficacy of this drug. However, concerns regarding the design 
of the trial has prevented wide-scale clinical adoption of the compound in therapeutic regimens. 
Additional supportive evidence for the effectiveness of immune-stimulation in osteosarcoma is 
the use of interferon(IFN)-α as adjuvant therapy, with encouraging results in historical cohorts 
of Scandinavian osteosarcoma patients [249]. In vitro data suggests that the positive effect may 
involve both immunological (as shown in chapter 6) and direct anti-tumor effects [190]. In the 
recently completed EURAMOS-1 clinical trial this drug was included in one of the randomized 
arms [278]. Preliminary data suggests no benefit, but follow-up of patients is ongoing [25].
Neither the mechanism of metastasis suppression by intratumoral macrophages in 
osteosarcoma is clarified, nor the contrast with epithelial tumors. It may be sought in the 
different flavors of macrophages that are distinguishable by specific markers. M1 are tumor 
suppressive, M2 support invasion, metastasis and angiogenesis of tumor cells. We assessed the 
nature of the tumor associated macrophages in osteosarcoma clinical samples using HLA-DRα, 
associated with M1 macrophages and CD163, a marker to distinguish M2. Surprisingly, both 
types of macrophages were present in the tumor tissues analyzed (Fig. 7.1). Recent perceptions 
on good vs. bad macrophages are more nuanced. Macrophages are flexible cells that polarize 
to a certain direction, but are not destined to stay that way (Fig. 1.5).
To complicate things even more, there was a recent report that macrophage infiltration in 
another primary bone tumor, Ewing sarcoma, predicts a poor prognosis [78]. Tumor associated 
macrophages are also associated with a poor prognosis in leiomyosarcoma and gastrointestinal 
stromal cell tumors [138;266]. The tumor microenvironment is conducive towards the generation 
of pro-tumor, immunosuppressive and pro-angiogenic M2 macrophages in many epithelial 
cancers and apparently also in some sarcoma types [208]. On the other hand, a pro-inflammatory 
tumor microenvironment can skew macrophage polarization towards M1 type macrophages with 
anti-tumor properties. Similar to epithelial cancers, high macrophage infiltration was associated 
with increased microvessel density in osteosarcoma, suggesting a similar role for M2 type 
macrophages in the promotion of angiogenesis. However, in the case of osteosarcoma, the influx 
of pro-angiogenic macrophages may be similar to a “Trojan horse.” Perhaps macrophages are 
attracted by the tumor to support angiogenesis, but following chemotherapeutic treatment, the 
release of endogenous danger signals by dying tumor cells causes the macrophages to become 
polarized toward an M1, anti-tumor phenotype (Fig. 7.2). This proposed mechanism is supported 
by the fact that the survival benefit of high macrophage infiltration as determined in chapter 4 
was partly dependent on the histological response to chemotherapy.
Coley’s toxins were denounced by another famous bone sarcoma expert, the pathologist 
James Ewing who gave his name to the second aggressive pediatric bone tumor [65]. Ewing was 
not charmed by the medieval treatment developed by Coley, he was a fervent proponent of 
radiation therapy, which was effective for many tumors, but not for osteosarcoma.
The relatively good response of sarcomas to immune stimulation and the favorable 
















tumor immunology is different for sarcomas. This does not seem attributable to a particular 
macrophage subtype, but lies in the nature of this tumor type. Few clinical trials have been 
conducted on immunotherapy in sarcomas. Given our findings that macrophages are 
associated with less metastases in osteosarcoma, tumor immunotherapy specifically targeted 
at this tumor type should be evaluated.
Activation of natural killer cells in immunotherapy of osteosarcoma
The ability of natural killer (NK) cells to lyze tumor cells without the need for prior sensitization is 
an attractive prospect for anticancer immunotherapy [148;186]. In chapters 5 and 6 we show that 
osteosarcoma cells are sensitive to lysis by both autologous and allogeneic NK cells. The antitumor 
activity of NK cells could be further augmented by activation with interleukin(IL)-15 and IFN-α. 
Importantly, chemotherapy resistant osteosarcoma cells retained their susceptibility to NK cell 
mediated lysis. Lysis of osteosarcoma cells by NK cells was dependent on Natural Killer Group 2, 
member D (NKG2D) and DNAX accessory molecule-1 (DNAM-1) but not on CD95. In many cancer 
types, systemic immunosuppression appears to influence the phenotype and effector capability 




Fig. 7.1 Osteosarcoma samples are infiltrated with CD14 and CD163 single and double positive macrophages. 
Spectral imaging was used to reduce autofluorescence of osteosarcoma cells. In the composite image, CD14-
positive cells are represented in green, CD163-positive cells are represented in red, and CD14/CD163 double 

























phenotypic characteristics and unimpaired native cytolytic function (chapter 5). In addition, patient 
derived NK cells can be adequately activated by cytokine treatment with IL-15 (chapter 5) or IFN-α 
(chapter 6). Therefore, activation of autologous NK cells (either in vivo or ex vivo) may be efficacious. 
However, since patients are treated with lymphodepleting chemotherapy, careful thought needs to 
be given regarding the optimal timing of adjuvant immunotherapeutic treatment.
A trial in which autologous activated NK cells were infused in melanoma and renal cell cancer 
patients demonstrated that NK cells persisted in the circulation for days to weeks following adoptive 
transfer [203]. Disappointingly, no clinical responses were seen, perhaps because of an observed 
down-regulation of the activating receptor NKG2D in vivo. In addition to cytolysis as a result of ligation 
of activating receptors, NK cells are capable of antibody-dependent cellular cytotoxicity (ADCC). 
Using the anti-epidermal growth factor receptor (EGFR) antibody cetuximab, osteosarcoma cells 























Fig. 7.2 Model depicting the pro-tumor M2 macrophage as a ‘Trojan horse’ which can polarize towards an anti-
















NK cell receptors. Perhaps the combination of the adoptive transfer of autologous NK cells and 
treatment with humanized monoclonal antibodies will yield the desired clinical results.
Although osteosarcoma cells were sensitive to lysis by autologous NK cells in vitro, there 
is some theoretical benefit of using allogeneic NK cells. NK cells are inhibited in their cytolytic 
activity when inhibitory killer cell immunoglobulin-like receptors (KIRs) recognize their cognate 
major histocompatibility complex (MHC) class I ligands (Fig. 1.6) [118]. KIR-ligand mismatch has 
been shown to contribute to NK cell cytolysis in vivo, for example in the setting of stem cell 
transplantion in acute myeloid leukemia (AML)-patients [173;270]. In line with this data, studies 
in mice show that KIR-ligand mismatched NK cells facilitate engraftment of hematopoietic 
transplants, and have increased graft-versus-leukemia efficacy and reduced graft-versus-host 
disease in comparison to NK cells without such a KIR-ligand mismatch [224]. Similar results were 
obtained in a murine breast cancer model employing haploidentical bone marrow and spleen 
transplantation [76]. In osteosarcoma, there is a relatively high level of MHC class I expression 
(Fig. 5.2, and [262]). Therefore, application of allogeneic NK cells with a KIR-ligand mismatch 
(for example in the setting of a haploidentical stem cell transplantation) will possibly result in a 
higher degree of tumor cell lysis than strategies aimed at the activation of autologous NK cells.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Despite multi-agent chemotherapy and wide margin surgery, high-grade osteosarcoma has a 
poor prognosis. In this thesis, data demonstrating a role for cells of the innate immune system in 
controlling and possibly treating high-grade osteosarcoma are presented. Future studies should 
be aimed at a better understanding of the interaction between tumor and host.  Tumor cells may 
influence migration, differentiation, polarization and activation of innate immune cells. Conversely, 
immune cells can have direct or indirect effects on viability, motility, invasion and migration of tumor 
cells. For example, immune cells can express cytokines and chemokines -such as CXCL12- which can 
bind to the receptors – in this case CXCR4- on tumor cells, with a potential to influence tumor cell 
viability and motility. There is substantial interconnectivity between these various aspects of tumor-
host interactions, which also involve other cells, such as endothelial cells and stromal cells.
As was shown in chapter 4, infiltration of macrophages in osteosarcoma is associated with 
a reduced risk of metastatic disease, but the exact biological mechanism in which macrophages 
inhibit (metastasis of) osteosarcoma tumor cells remains unclear. Both classically activated 
M1 type macrophages as well as alternatively activated M2 type macrophages are present 
in osteosarcoma. Using an in vitro co-culture system, the effect of osteosarcoma cells on 
the differentiation and polarization of monocytes and macrophages can be studied. In 
addition, cytotoxicity experiments can be performed to study if macrophages are able to lyse 
osteosarcoma cells and if this is dependent on the activation and polarization status (M1 vs. 
M2) of the effector cells. Upregulation of the SIRPα-ligand CD47 on myeloid leukemia cells 
resulted in reduced phagocytosis by macrophages, possibly contributing to immune evasion 
by the tumor [109]. Although the interaction between CD47 and SIRPα was not studied in this 

























upregulated in osteosarcoma patients with good prognosis. Perhaps specific blocking of CD47-
SIRPα interaction augments macrophage-mediated osteosarcoma cell phagocytosis.
A promising tool to study tumor-host interactions are xenograft models [182]. Freshly 
isolated tumor cells obtained from diagnostic biopsies can be transplanted in immunodeficient 
mice. If corresponding peripheral blood mononuclear cells (PBMCs) are available from these 
patients, these can be used to reconstitute the immune system of the recipient. This will allow 
for detailed study of tumor-immune cell interaction in an ‘autologous’ setting. Tumor growth 
can be monitored in the presence or absence of specific immune cell subsets. Using such 
an ‘autologous xenograft model’, several fundamental questions regarding the interaction 
between monocytes/macrophages and osteosarcoma cells can be answered. Do monocytes/
macrophages influence growth of osteosarcoma xenografts? If so, is this effect dependent on 
the presence of other immune cell subsets such as T cells, implicating a possible role of the 
adaptive immune system in tumor control? Does treatment with macrophage activating agents 
influence macrophage polarization and tumor outgrowth in this model? Using a humanized 
antibody, is there evidence of ADCC by monocytes/macrophages and/or NK cells in vivo? Is 
there an effect of monocytes/macrophages on angiogenesis in osteosarcoma and is this 
dependent on polarization status of the macrophages? 
In chapters 5 and 6, pre-clinical data regarding the efficacy of NK cells in the treatment 
of osteosarcoma are presented. As was discussed in paragraph 7.2.2, there is a theoretical 
advantage of the adoptive transfer of KIR-ligand mismatched allogeneic NK cells as opposed 
to the activation of autologous NK cells. Additional in vitro cytolytic experiments can 
determine if KIR-ligand mismatch also contributes to increased NK cell mediated cytotoxic 
activity in osteosarcoma. Xenograft models using immunodeficient mice with human NK 
cell reconstitution can be used to study efficacy of NK cells and NK cell activating agents in 
osteosarcoma lysis in vivo. Another potentially efficacious approach in augmenting NK cell 
mediated cytotoxicity is blocking the effect of non-KIR co-inhibitory receptors. For example, 
NK cells can express the inhibitory receptor PD-1 [289]. Perhaps blocking of this receptor might 
result in a better lysis of PD-1 ligand expressing tumor cells. 
A hurdle in successful application of NK cell activation or adoptive transfer in the 
immunotherapy is the infiltration of sufficient numbers of activated NK cells in the tumor. 
Zebrafish or murine xenografts with live cell imaging of labeled immune cells can be used to 
study migration of immune cells towards the tumor site. 
In addition to the preclinical studies, the results as presented in this thesis justify 
translation to clinical trials. Treatment with mifamurtide -a macrophage activating agent-, 
yielded promising clinical results [169;170], but it remains unknown which patient group 
would benefit most from treatment with macrophage activating agents. Perhaps treatment 
with a macrophage activating agent is only beneficial in patients that already have relatively 
large numbers of macrophages present in the tumor. Alternatively, activation of monocytes 
circulating in the peripheral blood could also result in enhanced intratumoral infiltration and 
subsequent antitumor activity of intratumoral macrophages and will thus (also) benefit patients 
















what is happening in situ during treatment with a monocyte/macrophage activating agent, 
the migration and activation status of monocytes/macrophages before, during and after 
treatment needs to be monitored. Patients with bilateral metastatic disease, eligible for multi-
step surgery, could undergo resection of metastatic lesions in one lung, followed by several 
weeks of treatment with a macrophage activating agent such as mifamurtide. Subsequently, 
the metastases in the contralateral lung could be resected. In this way, the numbers and 
activation status of macrophages infiltrating the tumor can be determined, both before and 
after treatment with a macrophage activating agent. PBMCs and plasma can be collected at 
several time-points to monitor the activation status of monocytes and cytokine levels during 
this process. This will yield important information regarding the mechanism of action of 
macrophages in inhibiting metastasis in osteosarcoma.
The safety and efficacy of NK-cell based immunotherapy in osteosarcoma should be 
addressed in a phase I/II clinical trial. A possible strategy could be the adoptive transfer 
of cytokine-activated donor NK cells in an allogeneic (especially haploidentical) stem cell 
transplantation setting. In this scenario, KIR-ligand mismatch will hopefully result in maximal 
efficacy. Alternatively, autologous NK cells can be activated by the administration of cytokines, 
either in vivo or ex vivo. IFN-signaling was unimpaired in PBMCs of osteosarcoma patients and 
osteosarcoma cells were efficiently killed by IFN- α activated NK cells (chapter 6). Preliminary 
results of the EURAMOS-1 trial however, did not show a clinical benefit of monotherapy with 
IFN-α in osteosarcoma patients with good histological response to neo-adjuvant chemotherapy 
[ 25]. The in vivo activation of NK cells might not be as effective as the ex vivo activation, possibly 
due to being able to achieve higher concentrations in vitro. Perhaps the adoptive transfer of 
cytokine-activated NK cells is more efficacious than the administration of cytokines to patients 
in an attempt to activate immune cells in vivo. 
In conclusion, the activation of innate immune cells such as macrophages and NK cells is a 
promising new adjuvant treatment strategy to treat patients with high-grade osteosarcoma. 
Using xenograft models, the interactions between tumor and host can be examined in more 
detail. Further studies should be aimed at the translation of pre-clinical data towards clinical trials 





























Hooggradig osteosarcoom is een agressieve vorm van botkanker die voornamelijk adolescenten 
en jong volwassenen treft. Het is een zeldzame tumor, met afhankelijk van de leeftijd een 
incidentie tussen de 1.7 en 8.4 per miljoen. Ondanks behandeling met chemotherapie en 
operatieve verwijdering van de tumor, overlijdt dertig tot veertig procent van de patiënten 
aan de ziekte, meestal ten gevolge van uitzaaiingen naar de longen. In dit proefschrift werden 
factoren gerelateerd aan de etiologie en prognose van het hooggradige osteosarcoom 
onderzocht (hoofdstuk 2 en 3). Daarnaast werd de interactie tussen specifieke cellen van het 
aangeboren afweersysteem en osteosarcoom onderzocht (hoofdstuk 4, 5 en 6). Gezamenlijk 
zullen deze studies hopelijk leiden tot de ontwikkeling van therapieën die de cellen van het 
aangeboren afweersysteem activeren en in staat stellen de groei van tumorcellen in te perken, 
dan wel de tumorcellen direct of indirect te doden.
In sommige gevallen van osteosarcoom is er sprake van een genetische predispositie, 
bijvoorbeeld zoals in het kader van het Li-Fraumeni syndroom (ten gevolge van TP53 mutaties) 
of het erfelijke retinoblastoom syndroom (ten gevolge van RB1 mutaties). In de meeste gevallen 
is er echter geen erfelijke oorzaak aan te wijzen. Slechts zelden is er in het bot een  pre-maligne 
afwijking aan te wijzen. Er zijn een aantal aanwijzingen dat mesenchymale stroma cellen (MSCs) 
of vroege osteoblast-precursorcellen de voorloper cellen zijn van osteosarcoomcellen. Ten 
eerste, vindt er in de groeischijven ten tijde van de pubertaire groeispurt een snelle celdeling en 
differentiatie van MSCs plaats. Het is op deze anatomische lokatie dat osteosarcoom het meest 
frequent ontstaat. Ten tweede is gebleken dat muizen MSCs die langdurig in vitro gekweekt 
zijn, zich kunnen ontwikkelen tot , osteosarcoom-achtige tumorcellen. Ook MSCs van apen 
(Macacus cynomolgus) ondergaan een dergelijke transformatie naar tumor-achtige cellen bij 
langdurig kweken. In hoofdstuk 2 wordt beschreven dat bij het langdurig kweken van MSCs 
van osteosarcoompatiënten, een dergelijke kwaadaardige ontaarding niet plaatsvond. Ondanks 
bijna twee jaar continue kweek, werd in geen van de MSC kweken de plotselinge toename van 
proliferatie gezien welke karakteristiek is voor in vitro maligne ontaarding. Wel ontstonden 
er, zowel in MSCs van gezonde donoren als in MSCs van osteosarcoompatiënten, gedurende 
het kweken binucleaire cellen. Bij genexpressieanalyse van lage passages MSCs bleek bij MSCs 
afkomstig van osteosarcoompatiënten een lagere expressie van “hematopoietic cell specific Lyn 
substrate 1” (HCLS1) dan MSCs afkomstig van gezonde donoren. Het eiwit afkomstig van HCLS1 
staat bekend om zijn rol bij B-cel receptor signalering en myelopoiese. Of verminderde expressie 
van dit gen in MSCs een rol speelt bij de ontwikkeling tot osteosarcoom is nog onbekend.
Behalve de differentiële expressie van HCLS1 waren de MSCs van osteosarcoompatiënten 
en gezonde donoren zeer overeenkomstig. Er zijn verschillende mogelijke oorzaken voor het 
feit dat er zo weinig verschillen tussen MSCs van osteosarcoompatiënten en gezonde donoren 
waren. Het zou zo kunnen zijn dat de hypothese dat het osteosarcoom uit MSCs ontstaat, niet 
juist is. Daarnaast zou het kunnen zijn dat op de plek waar de MSCs voor deze studie geoogst 
zijn (de bovenrand van het heupbeen) de cellen niet bovenmatig gevoelig voor maligne 
ontaarding zijn, terwijl voorlopercellen op andere plaatsen (in casu aan het uiteinde van de lange 
pijpbeenderen waar de tumoren zich bevinden) dit wel zijn. Deze lokatiespecifieke gevoeligheid 























bij somatisch mozaïcisme), of aan specifieke omgevingsfactoren in de buurt van de groeischijf 
(endocriene en paracriene signalering). Een andere mogelijke verklaring voor het uitblijven van 
oncogene transformatie tijdens langdurig kweken, is dat dit onvoldoende is om kwaadaardige 
ontaarding plaats te laten vinden. Er wordt algemeen aangenomen dat er meerdere ‘hits’ nodig 
zijn om een gezonde cel tot een tumorcel te laten verworden. Mogelijk dat lokaal aanwezige 
groeifactoren of additionele genetische of functionele veranderingen zoals verlies van celcyclus 
controle noodzakelijk zijn voordat transformatie optreedt. Ook indien de tumorontwikkeling niet 
volgens een stapsgewijze opeenstapeling van genetische fouten ontstaat, maar er een catastrofale 
chromosomale gebeurtenis genaamd ‘chromotripsis’ optreedt, moet deze waarschijnlijk in een 
voor kwaadaardige ontaarding gevoelige genetische of omgevingsachtergrond plaatsvinden.
In hoofdstuk 3 wordt beschreven welke factoren van prognostisch belang zijn voor de 
overleving van osteosarcoompatiënten met longmetastasen. Hieruit bleek, dat het aantal 
(histologisch vitale) longmetastasen en het mannelijke geslacht geassocieerd waren met een 
hogere kans op overlijden. In hoofdstuk 4 werd middels een genoombrede genexpressie 
analyse in een relatief groot cohort van osteosarcoompatiënten aangetoond dat indien er 
een hoge expressie van macrofaag-geassocieerde genen in tumorbiopten aanwezig was, dit 
geassocieerd was met een lager risico voor gemetastaseerde ziekte. De resultaten beschreven 
in deze hoofdstukken impliceren dat patiënten met morfologisch vitale en/of  een groot aantal 
metastasen baat zouden kunnen hebben bij immunotherapeutische strategieën die migratie 
naar en activatie van monocyten en macrofagen in osteosarcoom stimuleren.
De tumorgroei-bevorderende rol van tumor geassocieerde macrofagen in carcinomen 
is welbekend. Epitheliale tumoren met grote aantallen infiltrerende macrofagen hebben 
een slechtere prognose dan tumoren met weinig infiltrerende cellen, wat gerelateerd is aan 
de belangrijke rol die macrofagen spelen in de initiatie van angiogenese van deze tumoren. 
Macrofagen zijn zeer plastische cellen die, afhankelijk van hun omgeving en de activerende 
signalen die ze ontvangen, een tumor bevorderende of tumor inhiberende rol aan kunnen 
nemen. Cytokines zoals interferon (IFN)-γ en bacteriële cel(wand)producten zoals muramyl-
tri-peptide (MTP) kunnen macrofagen ‘klassiek’ activeren. Deze ‘klassiek geactiveerde’ M1-
macrofagen brengen pro-inflammatoire cytokines zoals interleukine (IL)-1, IL-6 en IL-12 tot 
expressie en kunnen tumorcellen direct doden door fagocytose, zuurstofradicalen en cytokine-
geïnduceerde cytotoxiciteit. Daarnaast kunnen zij NK en T cellen rekruteren en activeren 
en zo ook indirect voor tumorceldood zorgen. Door IL-4 en IL-13 ‘alternatief geactiveerde’ 
M2 macrofagen zijn belangrijk in weefselhomeostase en bevorderen wondgenezing en 
angiogenese. Het zijn deze M2 karakteristieken die vaak in verband gebracht worden met de 
‘pro-tumor’ kwaliteiten van tumor geassocieerde macrofagen.
Zoals beschreven in hoofdstuk 4, waren een aantal genen die hoog tot expressie kwamen in 
biopten afkomstig van patiënten zonder metastasen, specifieke macrofaagmarkers zoals CD14 
en MSR1. Daarnaast bleek een groot aantal van de genen die hoog tot expressie kwamen in deze 
prognostisch gunstigere groep geassocieerd met macrofaagfuncties zoals antigeen verwerking 
en presentatie. Middels aanvullende immunohistochemische en genexpressie studies werd 
















tumorcellen tot expressie gebracht werden. In aanvullende cohorten werd bevestigd dat een 
hogere infiltratie met macrofagen geassocieerd was met een betere overleving.
William B. Coley was een chirurg die bottumoren behandelde. In 1891 voerde hij de eerste 
succesvolle immunotherapeutische behandelingen uit door bij patiënten met inoperabele 
tumoren een mengsel van bacteriële toxines in de tumor te spuiten. De grootste successen 
met deze zogeheten ‘Coley’s toxines’ werden bij patiënten met tumoren van mesodermale 
origine, zoals osteosarcoom, geboekt. Ook meer recent zijn er aanwijzingen dat de klassieke 
activatie van macrofagen middels bacteriële celproducten tot een betere overleving van 
osteosarcoompatiënten leidt. Osteosarcoompatiënten met een postoperatieve wondinfectie 
hebben op de langere termijn een betere overleving, hetgeen bij muizenstudies afhankelijk 
van NK cellen en monocyten/macrofagen was. Een klinische trial waarbij liposomaal MTP 
(ook bekend onder de naam mifamurtide) werd toegevoegd aan de standaard adjuvante 
chemotherapeutische behandeling van osteosarcoompatiënten resulteerde in een significante 
verbetering in de zesjaarsoverleving van 70% naar 78%.
Het mechanisme waarmee macrofagen de metastasering in osteosarcoom direct of indirect 
inhiberen is nog niet opgehelderd. Zowel macrofagen met een M1 fenotype (met een hoge 
expressie van HLA-DRα) als macrofagen met een M2 fenotype (met een hoge expressie van CD163) 
waren aanwezig in osteosarcomen. Het aantal macrofagen in de tumor was positief gecorreleerd 
met zowel een betere histologische respons op chemotherapie, als met een groter aantal vaten 
in de tumor, een maat voor angiogenese. Mogelijk is de influx van macrofagen in osteosarcoom 
een ‘Trojaans paard’, waarbij ze als M2-type macrofagen de tumor ondersteunen door expressie 
van matrix metalloproteinasen (MMPs) en het beïnvloeden van de angiogenese. Ten gevolge 
van endogene (door immunogene celdood) of exogene (door de toediening van bijvoorbeeld 
MTP) ‘danger’ signalen kan vervolgens een verandering van fenotype richting een anti-tumor M1 
macrofaag plaatsvinden en wordt de aanvankelijke vriend, de vijand van de tumorcellen (Fig. 7.2).
In toekomstige studies dient het effect van osteosarcoomcellen op de differentiatie en 
polarisatie van monocyten en macrofagen en vice versa onderzocht te worden, zowel middels 
in vitro modellen als in in vivo xenograft modellen. Toekomstige klinische trials moeten zijn 
ontworpen om niet alleen de effectiviteit van macrofaag activerende agentia zoals mifamurtide 
te onderzoeken, maar ook de onderliggende mechanismen te bestuderen. Het onderzoeken van 
biologisch materiaal (perifere bloedcellen, serum en tumormateriaal) voorafgaand, gedurende en 
na de klinische trial is daarbij essentieel. Alleen dan kan antwoord worden gegeven op een aantal 
essentiële vragen. Ten eerste, maakt het aantal macrofagen dat bij aanvang van de behandeling 
aanwezig is in de tumor uit voor de effectiviteit van therapeutische macrofaagactivatie? Ten tweede, 
wat is de rol van chemotherapie en immunogene celdood van OS in de activatie van macrofagen? 
Ten derde, is er een rol voor de secundaire activatie van het adaptieve immuunsysteem in de 
effectiviteit van deze op het aangeboren immuunsysteem gerichte therapieën?
Natural killer (NK) cellen herkennen en doden virusgeïnfecteerde en getransformeerde cellen 
wanneer de balans tussen signalen afkomstig van activerende en inhiberende receptoren naar 
activatie overslaat (Fig. 1.6). Osteosarcoomcellen bleken in hoge mate gevoelig voor lysis door NK 























zoals IL-15 en IFN-α te activeren. Belangrijk was, dat ook chemotherapie-resistente cellen gevoelig 
waren voor lysis door NK cellen. NK cellen van osteosarcoompatiënten hadden een fenotype en een 
lytische capaciteit die vergelijkbaar was met NK cellen van gezonde donoren. Ook in een autologe 
setting was er enige cytolytische activiteit van NK cellen tegen de eigen osteosarcoomcellen, met 
een goede verbetering van de cytolytische activiteit na voorbehandeling met IL-15 of IFN- α. Deze 
resultaten impliceren dat zowel autologe als allogene geactiveerde NK cellen (hetzij in vivo dan 
wel ex vivo) een mogelijke effectieve therapie zou kunnen zijn voor osteosarcoompatiënten. Er 
is echter een theoretisch voordeel van het gebruiken van allogene NK cellen. NK cellen worden 
in hun cytolytische activiteit geïnhibeerd wanneer ‘killer cell immunoglobulin-like’ receptoren 
(KIRs) aan de bijbehorende ‘major histocompatibility complex’ (MHC) klasse 1 liganden binden. 
In een allogene setting, kan er sprake zijn van een ‘mismatch’ tussen de KIRs en de MHC klasse 
1 liganden, wat resulteert een vermindering van de inhiberende signalering en theoretisch een 
grotere effectiviteit van NK cel gebaseerde immunotherapie. Gezien de relatief hoge expressie 
van MHC klasse 1 op osteosarcoomcellen, zou dit een belangrijke overweging kunnen zijn in het 
ontwerpen van toekomstige klinische trials.
Een nog onbeantwoorde vraag is, of er in vivo voldoende migratie van NK cellen optreedt naar de 
tumorcellen om tot klinisch relevante tumorcellysis te leiden. Mogelijk dat xenograft modellen met 
het in beeld brengen van geïnfundeerde, gelabelde effector cellen hier een antwoord op kan geven. 
Ook kan in preklinische diermodellen onderzocht worden wat de  toegevoegde rol zou kunnen 
zijn voor ‘antibody dependent cellular toxicity’ (ADCC). Bij ADCC herkent een (gehumaniseerd) 
antilichaam de tumorcel en bindt vervolgens via het Fc-domein aan  speciale antilichaamreceptoren 
(Fc-receptoren) op monocyten of NK cellen. Dit concept is bestudeerd in in vitro studies waarbij 
bleek dat middels behandeling met het anti-EGFR antilichaam cetuximab op deze wijze een toename 
van de activiteit van NK cellen richting osteosarcoomcellen kon worden bereikt.
De veiligheid en effectiviteit van NK cel gebaseerde immunotherapeutische strategieën 
dient in fase I/II klinische trials verder onderzocht te worden. Een mogelijke strategie is de 
infusie van cytokine-geactiveerde donor NK cellen in een allogene (met name haplo-identieke) 
stamceltransplantatie-setting. Op deze wijze kan maximaal gebruik worden gemaakt van 
de KIR-ligand mismatch tussen donor en ontvanger en zal er hopelijk maximale anti-tumor 
effectiviteit worden behaald.
Nieuwe behandelingen voor patiënten met hooggradig osteosarcoom zijn hard nodig, 
zeker indien er sprake is van gemetastaseerd ziekte. De afgelopen twintig jaar is er nauwelijks 
verbetering in de overleving van deze vaak jonge patiëntengroep bereikt, ondanks hoge 
dosis chemotherapie en agressieve chirurgie. Het toepassen van immunotherapie is 
een veelbelovende strategie, met name in een multimodale setting gecombineerd met 
chemotherapie. Hierbij kan optimaal gebruik kan worden gemaakt van de immunogene 
celdood die door specifieke chemotherapie kan worden geïnduceerd, waarna (geactiveerde) 
immuuncellen verdere immunosurveillance en antitumor cytolysis kunnen zorgen. Vanwege de 
zeldzaamheid van deze tumor en de benodigde expertise in zowel behandeling als biological 
monitoring, dienen nieuwe therapieën vanuit expertise centra en idealiter in  internationaal 
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JAK  janus kinase
KIR  Killer Immunoglobulin-like Receptor
LIMMA  Linear Models for Microarray Data 
mDC  myeloid dendritic cell
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MFI  mean fluorescence intensity 


















MIC  major histocompatibility class I polypeptide-related sequence
MMP  matrix metalloproteinase
MRI  magnetic resonance imaging
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MTP  muramyl tripeptide
MTX  methotrexate
NCR  natural cytotoxicity receptor
NK cell  natural killer cell
NKG2D  Natural Killer Group 2, member D
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PAMP  pathogen associated molecular pattern
PBMC  peripheral blood mononuclear cell
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PE  phycoerythrin
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PVR  poliovirus receptor
RNA  ribonucleic acid 
RT  reverse transcriptase
SAM  Significance Analysis for Microarrays
STAT  signal transducer and activator of transcription
TAM  tumor associated macrophage
TGF-β  transforming growth factor- β
ULBP  UL-16 binding protein
VEGF  vascular endothelial growth factor 
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In de aanloop van het project, gedurende de drie labjaren en in de afrondingsfase daarna ben 
ik door velen geholpen. Ik hoop dat ik gaandeweg mijn waardering al heb laten blijken, maar ik 
maak toch graag van de gelegenheid gebruik om een aantal mensen met nadruk te bedanken.
Dr. A.C. Lankester, co-promotor. Arjan, fundamenteel onderzoek en klinisch werk gaan bij jou 
hand in hand, dat is een mooi voorbeeld dat ik ooit hoop te kunnen volgen. Dank voor de vrijheid 
die je me gaf om zelf (mede) de richting van het onderzoek te bepalen en in de afronding mijn 
eigen tempo te kiezen. Prof. Dr. P.C.W. Hogendoorn, promotor. Pancras, onder jouw vleugels 
zette ik als tweedejaars geneeskundestudent de eerste schreden in onderzoeksland. Ik vind 
het erg leuk dat jij niet alleen aan het begin van mijn onderzoekservaring een sturende rol hebt 
gehad, maar dat ook in opzet, uitvoering en voltooiing van deze promotie hebt gehad. Prof. Dr. 
R.M. Egeler, promotor. Maarten, in alle fasen van dit onderzoek heb jij me steeds met positieve 
bijdragen ondersteund. Ook vanuit Toronto waren jouw commentaren op de laatste onderdelen 
van dit proefschrift steeds bemoedigend, dank voor deze steun in de rug tijdens de laatste loodjes.
Dr. Cleton-Jansen en Dr. Schilham: Anne-Marie en Marco, jullie hebben beiden ontzettend veel 
betekend voor dit proefschrift. Marco, je kritische blik hebben veel dingen aangescherpt en 
beter gemaakt. Ettelijke keren waaide ik onaangekondigd met een vraag je kamer in en kon jij 
weer een lacune in mijn immunologie-kennis dichten, dank daarvoor. Anne-Marie, ik denk nog 
met veel plezier terug aan die keer dat jij letterlijk springend naast de microscoop stond toen 
we een binucleaire MSC hadden ontdekt. Dank voor je enthousiasme en positivisme.
Mijn lieve maatjes in het lab, Dagmar Berghuis en Willemijn Quispel, dank voor alle gezelligheid 
en steun, toen en nu! Wat fijn dat jullie mijn paranimfen willen zijn. Dagmar, niemand anders 
weet zó goed hoe het is een proefschrift over sarcoom-immunologie te verdedigen, het is een 
geruststellend idee dat jij tijdens de verdediging naast mij staat. Willemijn, jouw kritische blik 
en overdosis empathie waardeerde ik eerst als collega, waardeer ik nu als vriendin en maakt van 
jou straks ongetwijfeld een geweldige arts. 
Alle lab-collega’s van de kindergeneeskunde en de pathologie, bedankt voor de gezelligheid, 
collegialiteit en waar nodig praktische hulp. Riri, you are a very fun person to be around and I am 
honoured and grateful that you were the technician on this project. Susy, mede dankzij je Zuid-
Amerikaanse roots en je warme karakter heb ik me snel thuis gevoeld op het lab, muito obrigada! 
Mijn studenten Bas, Kimberly, Sharon, Joyce, Milou en Jolien: hoewel niet al jullie bijdragen de 
weg naar dit proefschrift gevonden hebben, heb ik van elk van jullie wat geleerd, dank daarvoor 
en dank voor jullie inzet. Alle mede-aio’s en P3-35 kamergenoten: dank voor de samenwerking 
en de fijne tijd. Alle huidige en voormalige collega's van de kindergeneeskunde in Leiden en Den 
Haag, dank voor de interesse en de bemoedigende woorden tijdens de afrondingsfase.
Speciale dank gaat uit naar de patiënten en hun ouders. Juist op het moment van het krijgen 
van een verpletterende diagnose waren er zovelen die onbaatzuchtig ‘ja’ zeiden op de vraag of 
ze mee wilden doen aan wetenschappelijk onderzoek. Zonder deze bijdrage waren de meeste 

















met het verkrijgen van informed consent en het verzamelen en verwerken van de biologische 
materialen, in het bijzonder Professor Hans Gelderblom, Professor Antonie Taminiau, Sander 
Dijkstra, Nicolette Leyerzapf, Karoly Szuhai, Daniëlle de Jong en Jakob Anninga.
Familie en vrienden, hier of op een zeker tropisch eiland, dank voor de broodnodige 
ontspanning naast het werk. Dank voor alle leuke weekenden, etentjes, vakanties, borrels en 
BBQs. Met name Juliëtte, Donnée, Liesbeth, Sandra en Marlies: dank!
Lieve ouders, goed voorbeeld doet goed volgen: jullie plezier en vasthoudendheid in het doen 
van onderzoek en het schrijven van boeken is inspirerend. Dit, en jullie onvoorwaardelijke 
steun, heeft zeker bijgedragen aan het voltooien van dit proefschrift.
Lieve Maarten, dank voor alles! Als arts zijn er grote hiaten in mijn moleculair biologische 
kennis, die jij onvermoeibaar opvult. Maar bovenal duizendmaal dank voor je steun en liefde, in 
voorspoedige en minder voorspoedige tijden. Wat bof ik.
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